Belgian Cancer Registry

CANCER FACT SHEET 2024
HEAD AND NECK CANCER
ICD-10 C00-C14; C30-C32

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

HPV: Human Papillomavirus is a sexually transmitted infection and a risk factor for the development of some H&N cancers.

H&N cancer is divided in sub-locations according to ICD-10 codes:

- **Lip:** C00
- **Oral cavity:** C02-C05.0; C06

- **Oropharynx:** C01; C05.1-C05.9; C09-C10
- **Nasopharynx:** C11
- **Hypopharynx:** C12-C13
- **Larynx:** C32
- **Nasal cavity and paranasal sinuses:** C30-C31
- **Salivary glands:** C07-C08
- **Other and ill-defined sites:** C14

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Head & Neck cancer incidence: by region 5

1.1.1. Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Head & Neck cancer incidence: by tumour stage 7

1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.2.4. Head & Neck cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

2. CANCER INCIDENCE TRENDS 12

2.1. Head & Neck cancer incidence trends: by region 12

2.1.1. Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 13

2.2. Head & Neck cancer incidence trends: by tumour stage 14

2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 14

2.3. Head & Neck cancer incidence trends: by age group 16

2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 16

2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

3. CANCER PREVALENCE 18

3.1. Head & Neck cancer prevalence: by region 18

3.1.1. Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 18

4. CANCER SURVIVAL 19

4.1. Head & Neck cancer survival: by region 19

4.1.1. Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 19

4.2. Head & Neck cancer survival: by sub-location and tumour stage 21

4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 21

4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024 28

4.2.4. Head & Neck cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2015-2024 35

5. CANCER SURVIVAL TRENDS 44
5.1. Head & Neck cancer survival trends: by tumour stage 44
5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024 44
6. CANCER MORTALITY 46
6.1. Head & Neck cancer mortality: by region 46
6.1.1. Head & Neck cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 46
7. CANCER MORTALITY TRENDS 48
7.1. Head & Neck cancer mortality trends: by region 48
7.1.1. Head & Neck cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 48
7.1.2. Head & Neck cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 50

1.1. Head & Neck cancer incidence: by region

1.1.1. Head & Neck cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																					ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	2	5	3	5	9	18	26	59	111	186	371	360	325	215	121	70	26	6	1,918	33.9
	[0.0]	[0.0]	[0.6]	[1.4]	[0.9]	[1.4]	[2.3]	[4.7]	[6.7]	[15.8]	[28.2]	[46.7]	[97.6]	[110.8]	[121.0]	[101.0]	[95.6]	[85.2]	[79.8]	[94.1]	[33.1]	(32.3; 35.4)
Brussels	0	0	0	1	0	1	0	2	5	2	16	16	24	26	26	13	5	2	1	0	140	32.8
	[0.0]	[0.0]	[0.0]	[2.6]	[0.0]	[1.9]	[0.0]	[4.2]	[11.0]	[4.5]	[38.8]	[44.2]	[81.2]	[119.5]	[153.1]	[101.0]	[60.8]	[39.5]	[44.5]	[0.0]	[22.9]	(27.2; 38.4)
Flanders	0	0	1	4	3	2	7	9	16	29	41	96	201	209	198	130	82	43	14	5	1,090	31.2
	[0.0]	[0.0]	[0.5]	[2.0]	[1.6]	[1.0]	[3.2]	[4.2]	[7.2]	[13.6]	[18.1]	[40.2]	[86.5]	[104.1]	[119.2]	[96.3]	[97.9]	[77.3]	[64.0]	[118.8]	[32.3]	(29.4; 33.1)
Wallonia	0	0	1	0	0	2	2	7	5	28	54	74	146	125	101	72	34	25	11	1	688	39.4
	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[1.8]	[1.7]	[5.9]	[4.3]	[24.0]	[42.9]	[59.9]	[123.7]	[122.1]	[118.1]	[110.7]	[98.4]	[116.5]	[129.7]	[62.3]	[38.1]	(36.4; 42.4)
Females																						
Belgium	2	1	3	3	2	3	7	6	22	22	40	59	131	156	117	122	47	39	17	9	808	12.7
	[0.7]	[0.3]	[0.9]	[0.9]	[0.6]	[0.8]	[1.8]	[1.6]	[5.7]	[5.9]	[10.4]	[15.0]	[33.9]	[45.2]	[39.2]	[47.7]	[27.0]	[28.8]	[23.6]	[41.6]	[13.5]	(11.9; 13.6)
Brussels	1	0	0	0	1	2	0	1	5	1	7	4	9	7	9	7	4	3	0	1	62	11.8
	[2.8]	[0.0]	[0.0]	[0.0]	[2.3]	[3.5]	[0.0]	[2.1]	[11.0]	[2.4]	[18.2]	[11.6]	[29.5]	[27.8]	[41.8]	[37.8]	[31.2]	[31.1]	[0.0]	[47.6]	[9.7]	(8.8; 14.8)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	1	0	2	2	0	0	6	4	11	13	18	28	77	94	57	76	31	22	13	5	460	12.0
	[0.6]	[0.0]	[1.1]	[1.1]	[0.0]	[0.0]	[2.7]	[1.9]	[4.9]	[6.2]	[8.1]	[12.0]	[33.2]	[45.5]	[32.2]	[49.1]	[28.3]	[25.4]	[28.7]	[38.8]	[13.4]	(10.9; 13.2)
Wallonia	0	1	1	1	1	1	1	1	6	8	15	27	45	55	51	39	12	14	4	3	286	14.1
	[0.0]	[1.0]	[0.9]	[0.9]	[0.9]	[0.9]	[0.8]	[0.8]	[5.1]	[6.8]	[12.0]	[21.6]	[36.4]	[48.6]	[51.1]	[47.1]	[23.3]	[35.8]	[19.0]	[45.2]	[15.2]	(12.5; 15.8)

1.2. Head & Neck cancer incidence: by tumour stage

1.2.2. Head & Neck cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	91 [2.7]	257 [26.4]	91 [19.8]	440 [7.6]	7.7 (7.0; 8.5)	52 [1.6]	95 [9.2]	49 [7.4]	197 [3.3]	3.2 (2.7; 3.6)
II	61 [1.8]	161 [16.5]	78 [16.9]	300 [5.2]	5.3 (4.7; 5.9)	22 [0.7]	65 [6.3]	40 [6.1]	128 [2.1]	2.0 (1.6; 2.3)
III	68 [2.0]	175 [18.0]	76 [16.5]	319 [5.5]	5.7 (5.1; 6.3)	17 [0.5]	60 [5.8]	35 [5.3]	112 [1.9]	1.7 (1.4; 2.1)
IV	164 [4.8]	394 [40.5]	150 [32.6]	709 [12.2]	12.4 (11.5; 13.3)	47 [1.4]	142 [13.8]	86 [13.0]	275 [4.6]	4.3 (3.8; 4.8)
X/NA	38 [1.1]	69 [7.1]	43 [9.3]	150 [2.6]	2.7 (2.3; 3.1)	26 [0.8]	42 [4.1]	24 [3.6]	96 [1.6]	1.5 (1.2; 1.8)

1.2.3. Head & Neck cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	76 [2.2]	170 [17.5]	64 [13.9]	311 [5.4]	5.4 (4.8; 6.1)	42 [1.3]	80 [7.8]	41 [6.2]	164 [2.7]	2.6 (2.2; 3.0)
II	21 [0.6]	52 [5.3]	31 [6.7]	104 [1.8]	1.9 (1.5; 2.2)	23 [0.7]	29 [2.8]	16 [2.4]	69 [1.2]	1.1 (0.8; 1.4)
III	22 [0.7]	54 [5.5]	17 [3.7]	93 [1.6]	1.6 (1.3; 2.0)	9 [0.3]	21 [2.0]	15 [2.3]	45 [0.8]	0.7 (0.5; 0.9)
IV	57 [1.7]	130 [13.4]	44 [9.6]	231 [4.0]	4.0 (3.5; 4.5)	16 [0.5]	52 [5.1]	37 [5.6]	105 [1.8]	1.6 (1.3; 2.0)
X/NA	246 [7.3]	650 [66.8]	282 [61.2]	1,179 [20.3]	20.9 (19.7; 22.1)	74 [2.2]	222 [21.6]	125 [19.0]	425 [7.1]	6.7 (6.0; 7.3)

1.2.4. Head & Neck cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	100 [3.0]	274 [28.1]	96 [20.8]	471 [8.1]	8.3 (7.5; 9.0)	55 [1.6]	107 [10.4]	54 [8.2]	217 [3.6]	3.5 (3.0; 3.9)
II	52 [1.5]	147 [15.1]	79 [17.2]	278 [4.8]	4.9 (4.4; 5.5)	27 [0.8]	59 [5.7]	37 [5.6]	124 [2.1]	1.9 (1.6; 2.3)
III	71 [2.1]	183 [18.8]	70 [15.2]	324 [5.6]	5.8 (5.1; 6.4)	16 [0.5]	60 [5.8]	37 [5.6]	113 [1.9]	1.8 (1.4; 2.1)
IV	169 [5.0]	397 [40.8]	158 [34.3]	725 [12.5]	12.7 (11.8; 13.6)	50 [1.5]	147 [14.3]	93 [14.1]	290 [4.9]	4.5 (4.0; 5.1)
X/NA	30 [0.9]	55 [5.7]	35 [7.6]	120 [2.1]	2.2 (1.8; 2.6)	16 [0.5]	31 [3.0]	13 [2.0]	64 [1.1]	1.0 (0.8; 1.3)

1.2.5. Head & Neck cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Lip C00	**I**	1 [0.0]	8 [0.8]	6 [1.3]	15 [0.3]	0.3 (0.1; 0.4)	2 [0.1]	3 [0.3]	6 [0.9]	11 [0.2]	0.2 (0.1; 0.3)
	II	0 [0.0]	2 [0.2]	5 [1.1]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	3 [0.5]	3 [0.1]	0.0 (0.0; 0.1)
	III	0 [0.0]	2 [0.2]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	X/NA	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
Oral cavity C02-C05.0;C06	**I**	26 [0.8]	61 [6.3]	10 [2.2]	98 [1.7]	1.7 (1.4; 2.0)	11 [0.3]	38 [3.7]	17 [2.6]	66 [1.1]	1.0 (0.8; 1.3)
	II	10 [0.3]	36 [3.7]	14 [3.0]	60 [1.0]	1.0 (0.8; 1.3)	12 [0.4]	17 [1.7]	14 [2.1]	43 [0.7]	0.7 (0.5; 0.9)
	III	18 [0.5]	42 [4.3]	15 [3.3]	75 [1.3]	1.3 (1.0; 1.6)	5 [0.1]	24 [2.3]	12 [1.8]	41 [0.7]	0.6 (0.4; 0.8)
	IV	46 [1.4]	122 [12.5]	35 [7.6]	203 [3.5]	3.5 (3.1; 4.0)	12 [0.4]	59 [5.7]	47 [7.1]	118 [2.0]	1.8 (1.5; 2.1)
	X/NA	4 [0.1]	2 [0.2]	3 [0.7]	9 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	1 [0.1]	2 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
Pharynx C01;C05.1-C05.9;C09-C13	**I**	37 [1.1]	95 [9.8]	22 [4.8]	154 [2.7]	2.7 (2.3; 3.1)	20 [0.6]	30 [2.9]	15 [2.3]	65 [1.1]	1.1 (0.8; 1.3)
	II	27 [0.8]	58 [6.0]	28 [6.1]	113 [1.9]	2.0 (1.6; 2.3)	6 [0.2]	27 [2.6]	14 [2.1]	47 [0.8]	0.7 (0.5; 0.9)
	III	35 [1.0]	86 [8.8]	33 [7.2]	154 [2.7]	2.7 (2.3; 3.2)	6 [0.2]	19 [1.8]	16 [2.4]	41 [0.7]	0.6 (0.4; 0.8)
	IV	85 [2.5]	205 [21.1]	66 [14.3]	357 [6.2]	6.2 (5.6; 6.9)	24 [0.7]	56 [5.4]	23 [3.5]	103 [1.7]	1.7 (1.3; 2.0)
	X/NA	2 [0.1]	24 [2.5]	13 [2.8]	39 [0.7]	0.7 (0.5; 0.9)	2 [0.1]	11 [1.1]	3 [0.5]	17 [0.3]	0.3 (0.1; 0.4)
Oropharynx C01;C05.1-C05.9;C09-C10	**I**	34 [1.0]	83 [8.5]	19 [4.1]	136 [2.3]	2.4 (2.0; 2.8)	19 [0.6]	28 [2.7]	14 [2.1]	61 [1.0]	1.0 (0.7; 1.2)
	II	23 [0.7]	41 [4.2]	22 [4.8]	86 [1.5]	1.5 (1.2; 1.8)	3 [0.1]	24 [2.3]	10 [1.5]	37 [0.6]	0.6 (0.4; 0.8)
	III	17 [0.5]	64 [6.6]	23 [5.0]	104 [1.8]	1.8 (1.5; 2.2)	5 [0.1]	12 [1.2]	13 [2.0]	30 [0.5]	0.5 (0.3; 0.6)
	IV	43 [1.3]	106 [10.9]	30 [6.5]	179 [3.1]	3.1 (2.6; 3.6)	14 [0.4]	42 [4.1]	18 [2.7]	74 [1.2]	1.2 (0.9; 1.5)
	X/NA	2 [0.1]	19 [2.0]	12 [2.6]	33 [0.6]	0.6 (0.4; 0.8)	2 [0.1]	11 [1.1]	3 [0.5]	16 [0.3]	0.2 (0.1; 0.4)
Nasopharynx C11	**I**	0 [0.0]	2 [0.2]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)

locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
	II	3 [0.1]	3 [0.3]	0 [0.0]	6 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	1 [0.1]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.2)
	III	12 [0.4]	3 [0.3]	2 [0.4]	17 [0.3]	0.3 (0.2; 0.4)	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	IV	12 [0.4]	10 [1.0]	2 [0.4]	25 [0.4]	0.4 (0.3; 0.6)	6 [0.2]	1 [0.1]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	2 [0.2]	1 [0.2]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
Hypopharynx C12-C13	**I**	3 [0.1]	10 [1.0]	3 [0.7]	16 [0.3]	0.3 (0.1; 0.4)	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	II	1 [0.0]	14 [1.4]	6 [1.3]	21 [0.4]	0.4 (0.2; 0.5)	1 [0.0]	2 [0.2]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
	III	6 [0.2]	19 [2.0]	8 [1.7]	33 [0.6]	0.6 (0.4; 0.8)	0 [0.0]	5 [0.5]	2 [0.3]	7 [0.1]	0.1 (0.0; 0.2)
	IV	30 [0.9]	89 [9.1]	34 [7.4]	153 [2.6]	2.7 (2.2; 3.1)	4 [0.1]	13 [1.3]	4 [0.6]	21 [0.4]	0.3 (0.2; 0.5)
	X/NA	0 [0.0]	3 [0.3]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Larynx C32	**I**	26 [0.8]	105 [10.8]	50 [10.9]	181 [3.1]	3.2 (2.8; 3.7)	5 [0.1]	19 [1.8]	10 [1.5]	34 [0.6]	0.5 (0.4; 0.7)
	II	10 [0.3]	38 [3.9]	20 [4.3]	68 [1.2]	1.2 (0.9; 1.5)	1 [0.0]	6 [0.6]	3 [0.5]	10 [0.2]	0.2 (0.1; 0.3)
	III	15 [0.4]	44 [4.5]	13 [2.8]	72 [1.2]	1.3 (1.0; 1.6)	4 [0.1]	17 [1.7]	6 [0.9]	27 [0.5]	0.4 (0.3; 0.6)
	IV	19 [0.6]	54 [5.5]	25 [5.4]	98 [1.7]	1.7 (1.4; 2.1)	5 [0.1]	23 [2.2]	2 [0.3]	30 [0.5]	0.5 (0.3; 0.7)
	X/NA	3 [0.1]	10 [1.0]	6 [1.3]	19 [0.3]	0.3 (0.2; 0.5)	1 [0.0]	4 [0.4]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)
Nasal cavity and paranasal sinuses C30-C31	**I**	2 [0.1]	3 [0.3]	5 [1.1]	10 [0.2]	0.2 (0.1; 0.3)	3 [0.1]	5 [0.5]	3 [0.5]	11 [0.2]	0.2 (0.1; 0.3)
	II	1 [0.0]	8 [0.8]	7 [1.5]	16 [0.3]	0.3 (0.2; 0.4)	1 [0.0]	2 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	III	2 [0.1]	7 [0.7]	2 [0.4]	11 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	0 [0.0]	3 [0.5]	4 [0.1]	0.1 (0.0; 0.1)
	IV	14 [0.4]	11 [1.1]	11 [2.4]	36 [0.6]	0.6 (0.4; 0.8)	7 [0.2]	6 [0.6]	11 [1.7]	24 [0.4]	0.4 (0.2; 0.5)
	X/NA	7 [0.2]	8 [0.8]	3 [0.7]	18 [0.3]	0.3 (0.2; 0.5)	9 [0.3]	8 [0.8]	3 [0.5]	20 [0.3]	0.3 (0.2; 0.5)
Salivary glands C07-C08	**I**	8 [0.2]	2 [0.2]	3 [0.7]	13 [0.2]	0.2 (0.1; 0.3)	14 [0.4]	12 [1.2]	3 [0.5]	30 [0.5]	0.5 (0.3; 0.7)
	II	4 [0.1]	5 [0.5]	5 [1.1]	14 [0.2]	0.3 (0.1; 0.4)	7 [0.2]	7 [0.7]	2 [0.3]	17 [0.3]	0.3 (0.1; 0.4)
	III	1 [0.0]	2 [0.2]	6 [1.3]	9 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	5 [0.1]	5 [0.5]	20 [4.3]	30 [0.5]	0.6 (0.4; 0.8)	2 [0.1]	3 [0.3]	9 [1.4]	14 [0.2]	0.2 (0.1; 0.3)

locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
	X/NA	13 [0.4]	7 [0.7]	8 [1.7]	28 [0.5]	0.5 (0.3; 0.7)	3 [0.1]	3 [0.3]	4 [0.6]	10 [0.2]	0.2 (0.1; 0.2)
Other and ill-defined sites C14	I	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	X/NA	1 [0.0]	4 [0.4]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	3 [0.3]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)

2.1. Head & Neck cancer incidence trends: by region

2.1.1. Head & Neck cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	1,953	1,857	1,780	1,982	1,955	1,969	1,839	2,027	1,969	1,996	2,019	1,966	2,018	2,010	1,989	2,073	1,833	1,953	1,933	1,900	1,918		
	CR	38.4	36.3	34.6	38.3	37.4	37.4	34.6	37.7	36.4	36.6	36.9	35.7	36.4	36.1	35.5	36.8	32.4	34.4	33.9	33.0	33.1		
	ESR2013	44.6	41.9	39.3	43.1	42.0	42.1	38.7	42.0	40.1	40.0	40.2	38.6	39.0	38.3	37.7	38.7	33.9	35.7	34.9	34.0	33.9	-1.2 (-1.4; -0.9)	2004-2024
Brussels	**N**	168	161	173	200	163	160	160	176	155	166	168	171	175	152	141	161	132	153	153	159	140		
	CR	35.0	33.3	35.3	40.3	32.3	31.0	30.4	32.4	28.0	29.6	29.6	29.9	30.2	26.1	24.0	27.2	22.1	25.5	25.5	26.1	22.9		
	ESR2013	46.4	45.0	48.6	55.4	45.2	44.2	43.1	47.5	41.2	42.3	44.1	43.9	43.9	39.1	34.3	39.7	32.3	38.0	35.8	37.8	32.8	-1.8 (-2.4; -1.2)	2004-2024
Flanders	**N**	1,062	970	973	1,017	1,023	1,055	1,004	1,080	1,059	1,122	1,112	1,074	1,084	1,110	1,122	1,178	1,047	1,091	1,102	1,073	1,090		
	CR	35.8	32.6	32.5	33.7	33.7	34.4	32.5	34.7	33.8	35.6	35.1	33.7	33.9	34.5	34.6	36.1	31.9	33.1	33.2	32.0	32.3		
	ESR2013	40.8	36.5	35.7	36.8	36.5	37.6	35.0	37.3	35.8	37.0	36.4	34.5	34.5	34.5	34.9	36.0	31.8	32.6	32.4	31.2	31.2	-0.9 (-1.2; -0.6)	2004-2024
Wallonia	**N**	723	726	634	765	769	754	675	771	755	708	739	721	759	748	726	734	654	709	678	668	688		
	CR	44.1	44.1	38.3	45.9	45.8	44.7	39.7	45.0	43.8	40.8	42.4	41.2	43.2	42.4	41.0	41.3	36.7	39.7	37.8	37.1	38.1		
	ESR2013	51.5	51.5	43.2	51.9	52.1	50.2	44.8	49.5	48.2	45.0	46.3	45.0	46.5	45.9	43.9	43.6	38.3	41.4	39.5	38.4	39.4	-1.4 (-1.8; -1.0)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Head & Neck cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	557	560	533	547	587	637	616	667	694	653	687	739	697	705	760	711	708	840	777	782	808		
	CR	10.5	10.5	9.9	10.1	10.8	11.6	11.1	12.0	12.3	11.6	12.1	13.0	12.2	12.3	13.2	12.3	12.1	14.4	13.2	13.2	13.5		
	ESR2013	10.9	10.9	10.4	10.4	11.0	12.0	11.4	12.1	12.5	11.6	12.2	12.9	12.0	12.0	12.8	11.9	11.8	13.8	12.7	12.5	12.7	0.9 (0.6; 1.3)	2004-2024
Brussels	**N**	61	67	71	51	56	66	66	70	72	54	54	71	62	69	78	59	50	64	59	63	62		
	CR	11.7	12.8	13.4	9.5	10.3	12.0	11.7	12.1	12.3	9.1	9.0	11.8	10.2	11.3	12.7	9.6	8.1	10.3	9.5	10.0	9.7		
	ESR2013	13.4	14.8	16.1	11.4	12.4	14.6	14.3	14.5	15.2	10.9	11.3	14.2	12.3	14.1	16.0	11.7	10.2	12.7	12.0	12.5	11.8	-0.8 (-1.7; 0.1)	2004-2024
Flanders	**N**	268	286	249	270	289	307	310	335	359	365	347	389	368	355	411	394	398	430	434	440	460		
	CR	8.8	9.3	8.1	8.7	9.3	9.8	9.8	10.5	11.2	11.3	10.7	11.9	11.2	10.8	12.4	11.8	11.9	12.8	12.8	12.9	13.4		
	ESR2013	9.0	9.6	8.2	8.7	9.1	9.8	9.8	10.3	10.8	11.0	10.3	11.4	10.6	10.0	11.5	11.0	11.0	11.8	11.8	11.6	12.0	1.6 (1.2; 2.0)	2004-2024
Wallonia	**N**	228	207	213	226	242	264	240	262	263	234	286	279	267	281	271	258	260	346	284	279	286		
	CR	13.1	11.8	12.1	12.8	13.6	14.8	13.3	14.5	14.4	12.8	15.6	15.2	14.5	15.2	14.6	13.9	14.0	18.6	15.2	14.8	15.2		
	ESR2013	13.7	12.5	12.7	13.3	14.2	15.3	13.5	14.8	14.8	13.0	15.7	15.2	14.2	15.2	14.2	13.5	13.5	17.8	14.6	13.9	14.1	0.5 (-0.1; 1.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Head & Neck cancer incidence trends: by tumour stage

2.2.3. Head & Neck cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	428	491	450	491	471			196	239	204	207	217		
	CR	7.6	8.6	7.9	8.5	8.1			3.4	4.1	3.5	3.5	3.6		
	ESR2013	8.0	9.1	8.1	8.8	8.3	1.8 (1.1; 2.6)	2004-2024	3.3	4.0	3.4	3.4	3.5	5.0 (4.3; 5.8)	2004-2024
														9.4 (6.8; 12.0)	2004-2011
														2.7 (1.5; 4.0)	2012-2024
II	**N**	255	299	308	282	278			103	127	133	153	124		
	CR	4.5	5.3	5.4	4.9	4.8			1.8	2.2	2.3	2.6	2.1		
	ESR2013	4.7	5.5	5.6	5.1	4.9	0.9 (0.3; 1.5)	2004-2024	1.7	2.1	2.2	2.4	1.9	3.0 (2.3; 3.7)	2004-2024
III	**N**	318	303	326	299	324			110	141	120	102	113		
	CR	5.6	5.3	5.7	5.2	5.6			1.9	2.4	2.0	1.7	1.9		
	ESR2013	5.9	5.6	5.9	5.4	5.8	0.3 (-0.2; 0.9)	2004-2024	1.8	2.3	2.0	1.6	1.8	2.5 (1.5; 3.4)	2004-2024
IV	**N**	742	723	738	729	725			239	277	278	269	290		
	CR	13.1	12.7	12.9	12.7	12.5			4.1	4.7	4.7	4.5	4.9		
	ESR2013	13.6	13.2	13.3	12.9	12.7	-0.5 (-0.8; -0.1)	2004-2024	3.9	4.5	4.4	4.2	4.5	1.9 (1.3; 2.5)	2004-2024
							1.8 (1.2; 2.5)	2004-2015						4.5 (3.3; 5.7)	2004-2015
							-3.2 (-4.0; -2.4)	2016-2024						-1.2 (-2.6; 0.3)	2016-2024
X/NA	**N**	90	137	111	99	120			60	56	42	51	64		
	CR	1.6	2.4	1.9	1.7	2.1			1.0	1.0	0.7	0.9	1.1		
	ESR2013	1.7	2.5	2.0	1.8	2.2	-10.1 (-11.1; -9.1)	2004-2024	1.0	0.9	0.7	0.8	1.0	-7.9 (-9.0; -6.8)	2004-2024
														-5.6 (-10.9; 0.0)	2004-2009

Stage	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
													-12.6 (-17.5; -7.5)	2010-2013
													-7.2 (-9.1; -5.2)	2014-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Head & Neck cancer incidence trends: by age group

2.3.4. Head & Neck cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	953	880	834	897	857	847	742	816	803	780	716	700	688	655	626	633	530	546	493	469	422		
	CR	29.8	27.4	25.9	27.7	26.3	25.9	22.6	24.7	24.2	23.5	21.5	21.0	20.6	19.6	18.8	19.0	15.9	16.3	14.7	13.9	12.5		
	ESR2013	31.8	29.0	26.9	28.8	27.3	26.7	23.2	25.2	24.5	23.6	21.4	20.7	20.3	19.2	18.3	18.4	15.4	15.9	14.3	13.8	12.4	-4.2 (-4.5; -3.9)	2004-2024
																							-3.2 (-3.8; -2.5)	2004-2015
																							-5.5 (-6.3; -4.8)	2016-2024
60-74	**N**	722	707	685	809	795	796	766	896	865	895	958	924	1,001	1,016	1,014	1,045	932	1,024	1,022	1,023	1,056		
	CR	106.1	103.2	99.7	115.6	111.6	109.5	103.3	118.5	112.4	114.2	120.2	113.7	120.2	118.6	115.3	116.3	101.6	109.6	108.1	106.7	108.5		
	ESR2013	106.4	103.3	99.7	114.9	110.3	109.8	103.1	118.2	111.8	113.2	118.6	113.1	120.3	118.3	115.6	116.3	101.9	109.9	108.0	107.5	109.1	0.1 (-0.2; 0.5)	2004-2024
																							1.1 (0.5; 1.8)	2004-2015
																							-1.1 (-1.9; -0.3)	2016-2024
75+	**N**	275	269	259	274	302	324	328	312	299	320	342	338	325	337	348	393	371	382	417	406	438		
	CR	93.8	88.9	82.5	84.1	89.7	93.8	92.6	86.4	81.0	85.1	89.2	86.3	82.3	85.4	87.6	97.3	89.7	91.8	96.7	91.2	95.1		
	ESR2013	92.8	87.8	78.1	80.9	87.4	92.7	89.8	85.6	81.7	83.9	88.7	86.2	80.3	84.0	88.5	96.5	89.9	91.9	96.7	90.7	94.8	0.4 (0.0; 0.9)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.5. Head & Neck cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	245	236	240	254	257	275	257	262	271	233	250	249	196	215	217	206	198	237	214	184	164		
	CR	7.8	7.5	7.6	8.0	8.0	8.5	7.9	8.0	8.3	7.1	7.6	7.6	6.0	6.5	6.6	6.3	6.0	7.2	6.5	5.5	4.9		
	ESR2013	8.1	7.8	7.8	8.2	8.2	8.7	8.1	8.1	8.3	7.1	7.5	7.5	5.8	6.4	6.4	6.1	5.9	7.1	6.4	5.5	4.9	-1.7 (-2.4; -1.1)	2004-2024
																							2.4 (-1.4; 6.3)	2004-2008
																							-2.7 (-3.5; -2.0)	2009-2024
60-74	**N**	187	197	186	177	196	237	223	250	284	271	294	325	325	310	342	322	325	391	365	368	404		
	CR	24.1	25.4	24.1	22.7	24.9	29.6	27.5	30.4	34.0	32.0	34.3	37.3	36.4	33.8	36.4	33.6	33.3	39.3	36.3	36.2	39.2		
	ESR2013	24.1	25.6	24.4	22.7	24.8	29.7	27.5	30.3	33.8	31.9	34.1	37.2	36.4	33.8	36.3	33.6	33.2	39.4	36.4	36.3	39.3	2.5 (2.0; 2.9)	2004-2024
																							3.9 (3.0; 4.9)	2004-2015
																							0.7 (-0.5; 1.9)	2016-2024
75+	**N**	124	127	104	114	133	122	134	152	138	147	142	163	174	180	199	182	182	210	197	228	234		
	CR	23.9	23.9	19.1	20.5	23.3	21.1	22.8	25.6	23.0	24.3	23.3	26.4	28.2	29.4	32.6	29.6	29.3	33.9	31.1	35.3	35.5		
	ESR2013	24.3	23.9	19.1	20.2	23.5	21.4	23.2	25.5	22.8	24.1	23.6	26.1	28.2	29.7	33.6	30.4	30.8	34.9	32.4	35.7	36.5	2.4 (1.8; 3.1)	2004-2024
																							-1.1 (-3.8; 1.6)	2004-2009
																							3.7 (2.9; 4.5)	2010-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Head & Neck cancer prevalence: by region

3.1.1. Head & Neck cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	1,640	6,141	9,663	11,725	12,913	703	2,658	4,192	5,158	5,758
	CR	28.1	105.3	165.7	201	221	11.7	44.3	69.9	86	96
	ESR2013	28.5	106.7	168.5	204.9	226.2	11.0	41.8	65.6	80.6	89.8
Brussels	**N**	118	456	733	903	999	54	206	356	449	498
	CR	19.2	74.1	119.1	146.7	162.3	8.4	32.2	55.6	70.1	77.8
	ESR2013	26.7	104.0	170.8	214.3	239.5	10.2	39.8	68.9	86.7	95.8
Flanders	**N**	946	3,570	5,641	6,893	7,603	404	1,499	2,358	2,883	3,193
	CR	27.8	105.0	165.9	202.7	223.6	11.7	43.3	68.1	83.2	92.2
	ESR2013	26.6	100.7	159.2	194.6	214.9	10.5	39.2	61.2	74.7	82.7
Wallonia	**N**	576	2,115	3,289	3,929	4,311	245	953	1,478	1,826	2,067
	CR	31.7	116.5	181.2	216.5	237.5	13.0	50.4	78.2	96.6	109.4
	ESR2013	32.5	118.7	185.6	222.5	244.8	12.0	47.0	72.4	89.3	101.1

4.1. Head & Neck cancer survival: by region

4.1.1. Head & Neck cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		25,805	80.4% (79.9%; 80.9%)	64.7% (64.0%; 65.4%)	57.0% (56.2%; 57.8%)	44.0% (42.2%; 45.8%)
Males						
Belgium	**All ages 15+**	18,618	80.2% (79.5%; 80.8%)	63.5% (62.7%; 64.3%)	55.3% (54.4%; 56.3%)	41.7% (39.6%; 43.9%)
	15-59	5,525	85.7% (84.8%; 86.7%)	68.7% (67.5%; 70.0%)	60.2% (58.8%; 61.6%)	47.9% (45.9%; 49.9%)
	60-74	9,562	79.6% (78.7%; 80.4%)	62.7% (61.7%; 63.8%)	53.7% (52.5%; 54.9%)	39.7% (37.8%; 41.7%)
	75+	3,659	73.1% (71.5%; 74.8%)	57.1% (54.9%; 59.3%)	51.5% (48.7%; 54.5%)	36.0% (27.9%; 46.5%)
Brussels	**All ages 15+**	1,473	77.9% (75.7%; 80.2%)	62.2% (59.4%; 65.2%)	55.2% (52.0%; 58.6%)	42.9% (36.2%; 50.8%)
	15-59	516	85.7% (82.7%; 88.9%)	69.7% (65.6%; 74.0%)	64.7% (60.3%; 69.5%)	53.6% (47.5%; 60.4%)
	60-74	683	75.3% (72.0%; 78.8%)	58.3% (54.3%; 62.6%)	46.9% (42.6%; 51.7%)	33.1% (26.7%; 41.2%)
	75+	282	70.2% (64.4%; 76.6%)	57.6% (50.2%; 66.1%)	57.1% (47.8%; 68.1%)	45.7% (25.6%; 81.5%)
Flanders	**All ages 15+**	10,451	81.4% (80.6%; 82.2%)	65.6% (64.6%; 66.7%)	57.3% (56.0%; 58.5%)	43.7% (41.1%; 46.5%)
	15-59	2,792	87.1% (85.8%; 88.4%)	72.3% (70.6%; 74.1%)	63.9% (61.9%; 65.8%)	50.2% (47.5%; 53.1%)
	60-74	5,408	81.0% (79.9%; 82.1%)	64.1% (62.7%; 65.5%)	55.4% (53.8%; 57.0%)	43.0% (40.5%; 45.5%)
	75+	2,326	75.1% (73.1%; 77.2%)	60.5% (57.8%; 63.3%)	52.6% (49.0%; 56.4%)	35.7% (26.9%; 47.5%)
Wallonia	**All ages 15+**	6,697	78.7% (77.7%; 79.8%)	60.4% (59.1%; 61.7%)	52.3% (50.8%; 53.8%)	38.2% (34.7%; 42.2%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	2,217	84.0% (82.4%; 85.5%)	64.0% (62.0%; 66.2%)	54.6% (52.4%; 57.0%)	43.7% (40.8%; 46.8%)
	60-74	3,472	78.2% (76.8%; 79.7%)	61.4% (59.6%; 63.3%)	52.4% (50.4%; 54.5%)	36.1% (32.9%; 39.5%)
	75+	1,052	69.6% (66.5%; 72.8%)	49.2% (45.3%; 53.5%)	47.6% (42.7%; 53.1%)	32.7% (18.3%; 58.4%)
Females						
Belgium	**All ages 15+**	7,187	81.0% (80.1%; 82.0%)	67.9% (66.7%; 69.1%)	61.4% (60.0%; 62.9%)	50.2% (47.0%; 53.5%)
	15-59	2,004	90.2% (88.8%; 91.5%)	79.6% (77.8%; 81.4%)	73.1% (71.0%; 75.3%)	61.7% (58.5%; 65.1%)
	60-74	3,329	82.6% (81.3%; 83.9%)	67.7% (66.0%; 69.5%)	59.8% (57.9%; 61.8%)	44.2% (41.1%; 47.6%)
	75+	1,892	68.7% (66.4%; 71.1%)	55.6% (52.8%; 58.6%)	51.4% (47.8%; 55.2%)	48.0% (38.2%; 60.2%)
Brussels	**All ages 15+**	620	80.9% (77.6%; 84.2%)	68.0% (63.9%; 72.3%)	61.5% (56.9%; 66.6%)	46.2% (38.8%; 54.9%)
	15-59	202	93.2% (89.7%; 96.8%)	85.2% (80.2%; 90.4%)	82.1% (76.5%; 88.1%)	69.2% (58.5%; 81.8%)
	60-74	259	81.0% (76.2%; 86.1%)	64.7% (58.7%; 71.4%)	58.5% (51.9%; 65.9%)	45.4% (35.9%; 57.4%)
	75+	162	65.6% (58.0%; 74.1%)	50.3% (41.8%; 60.7%)	39.9% (29.9%; 53.3%)	16.2% (6.7%; 39.2%)
Flanders	**All ages 15+**	3,900	82.4% (81.1%; 83.7%)	69.9% (68.3%; 71.6%)	62.9% (61.0%; 65.0%)	54.0% (49.2%; 59.1%)
	15-59	1,000	90.9% (89.1%; 92.7%)	82.0% (79.6%; 84.5%)	75.6% (72.8%; 78.6%)	66.0% (61.9%; 70.4%)
	60-74	1,780	84.8% (83.1%; 86.5%)	70.3% (68.1%; 72.7%)	62.0% (59.4%; 64.7%)	47.1% (42.9%; 51.7%)
	75+	1,141	71.3% (68.4%; 74.3%)	58.5% (54.9%; 62.4%)	52.6% (48.0%; 57.6%)	53.9% (40.6%; 71.5%)
Wallonia	**All ages 15+**	2,667	79.1% (77.4%; 80.7%)	64.9% (62.9%; 67.0%)	59.2% (56.9%; 61.6%)	45.4% (41.3%; 50.1%)
	15-59	802	88.5% (86.2%; 90.7%)	75.2% (72.1%; 78.4%)	67.9% (64.4%; 71.5%)	54.1% (48.7%; 60.1%)
	60-74	1,290	79.9% (77.7%; 82.2%)	64.7% (62.0%; 67.6%)	56.9% (53.9%; 60.2%)	40.0% (35.1%; 45.5%)
	75+	589	64.6% (60.4%; 69.0%)	51.3% (46.3%; 56.8%)	51.8% (45.6%; 58.8%)	45.9% (32.3%; 65.1%)

4.2. Head & Neck cancer survival: by sub-location and tumour stage

4.2.2. Head & Neck cancer survival by sub-location, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
location	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	25,805	80.4% (79.9%; 80.9%)	70.6% (70.0%; 71.3%)	64.7% (64.0%; 65.4%)	60.4% (59.7%; 61.2%)	57.0% (56.2%; 57.8%)	44.0% (42.2%; 45.8%)
Males								
Head & Neck (C00-C14, C30-C32)	**All**	18,618	80.2% (79.5%; 80.8%)	69.9% (69.2%; 70.6%)	63.5% (62.7%; 64.3%)	58.9% (58.1%; 59.8%)	55.3% (54.4%; 56.3%)	41.7% (39.6%; 43.9%)
	I	3,730	96.0% (95.2%; 96.8%)	91.2% (90.0%; 92.4%)	87.0% (85.5%; 88.6%)	83.6% (81.7%; 85.5%)	80.2% (78.1%; 82.4%)	66.8% (59.9%; 74.5%)
	II	2,731	90.7% (89.5%; 92.0%)	83.0% (81.3%; 84.7%)	76.1% (74.2%; 78.1%)	71.7% (69.5%; 73.9%)	67.2% (64.8%; 69.7%)	50.1% (42.4%; 59.1%)
	III	2,958	82.0% (80.5%; 83.5%)	72.0% (70.2%; 73.8%)	65.6% (63.6%; 67.6%)	60.8% (58.7%; 63.0%)	56.8% (54.5%; 59.3%)	41.0% (37.2%; 45.0%)
	IV	7,451	67.4% (66.3%; 68.5%)	52.8% (51.6%; 54.0%)	44.8% (43.6%; 46.1%)	39.9% (38.7%; 41.2%)	35.9% (34.6%; 37.2%)	24.5% (22.7%; 26.4%)
	X/NA	2,416	79.6% (77.8%; 81.3%)	69.4% (67.3%; 71.4%)	63.6% (61.4%; 65.9%)	58.3% (55.9%; 60.7%)	56.1% (53.6%; 58.7%)	43.2% (38.5%; 48.6%)
Lip (C00)	**All**	317	94.0% (90.5%; 97.6%)	90.2% (85.5%; 95.2%)	87.9% (82.1%; 94.2%)	87.0% (80.3%; 94.3%)	86.2% (78.6%; 94.5%)	74.5% (53.4%; 104.1%)
	I	144	98.0% (93.9%; 102.3%)	96.9% (90.9%; 103.2%)	95.2% (87.0%; 104.2%)	96.3% (87.1%; 106.4%)	92.9% (82.0%; 105.2%)	81.6% (61.6%; 108.1%)
	II	37	N<50	N<50	N<50	N<50	N<50	N<50
	III	21	N<50	N<50	N<50	N<50	N<50	N<50
	IV	19	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	96	95.0% (89.0%; 101.4%)	93.0% (85.1%; 101.7%)	88.8% (78.9%; 100.0%)	83.1% (70.9%; 97.4%)	82.9% (69.6%; 98.8%)	77.5% (45.1%; 133.2%)
Oral cavity (C02-C05.0, C06)	**All**	4,339	80.4% (79.2%; 81.7%)	69.9% (68.4%; 71.4%)	63.0% (61.4%; 64.7%)	57.8% (56.1%; 59.6%)	53.6% (51.8%; 55.5%)	42.3% (39.3%; 45.5%)
	I	816	95.4% (93.7%; 97.2%)	88.1% (85.5%; 90.8%)	82.6% (79.4%; 85.8%)	77.3% (73.6%; 81.1%)	72.6% (68.5%; 77.0%)	68.1% (61.6%; 75.3%)
	II	696	90.8% (88.4%; 93.2%)	82.3% (79.2%; 85.7%)	74.0% (70.3%; 78.0%)	68.5% (64.3%; 72.9%)	62.9% (58.3%; 67.8%)	49.6% (41.8%; 58.8%)
	III	667	80.7% (77.6%; 84.0%)	70.4% (66.7%; 74.3%)	63.2% (59.2%; 67.5%)	57.0% (52.7%; 61.6%)	52.8% (48.2%; 57.9%)	38.6% (31.0%; 48.2%)
	IV	1,724	68.6% (66.4%; 70.9%)	54.5% (52.1%; 57.1%)	47.1% (44.6%; 49.8%)	42.2% (39.6%; 44.9%)	38.1% (35.4%; 40.9%)	25.3% (21.3%; 30.0%)

Net Survival Probability, 2015-2024								
location	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	507	82.0% (78.5%; 85.7%)	73.1% (68.9%; 77.5%)	67.7% (63.2%; 72.6%)	62.4% (57.4%; 67.8%)	59.5% (54.2%; 65.3%)	46.9% (39.0%; 56.3%)
Pharynx (C01, C05.1-C05.9, C09-C13)	**All**	8,062	75.5% (74.5%; 76.5%)	63.2% (62.0%; 64.3%)	55.9% (54.7%; 57.1%)	51.1% (49.9%; 52.4%)	47.0% (45.7%; 48.3%)	33.6% (31.5%; 35.7%)
	I	1,080	93.5% (91.8%; 95.2%)	85.5% (83.1%; 88.0%)	81.4% (78.6%; 84.3%)	77.2% (74.0%; 80.6%)	73.7% (70.0%; 77.5%)	57.6% (48.8%; 67.9%)
	II	1,052	88.6% (86.5%; 90.7%)	80.7% (78.1%; 83.5%)	73.0% (69.9%; 76.3%)	69.1% (65.7%; 72.6%)	63.4% (59.7%; 67.4%)	46.1% (39.2%; 54.2%)
	III	1,355	81.8% (79.6%; 84.0%)	71.2% (68.6%; 73.9%)	65.4% (62.6%; 68.4%)	61.4% (58.4%; 64.5%)	57.5% (54.3%; 60.9%)	42.2% (37.1%; 48.0%)
	IV	4,050	65.9% (64.4%; 67.4%)	50.7% (49.1%; 52.3%)	42.2% (40.6%; 43.9%)	37.6% (35.9%; 39.3%)	33.5% (31.8%; 35.2%)	23.4% (21.2%; 25.8%)
	X/NA	694	70.7% (67.3%; 74.3%)	56.6% (52.9%; 60.7%)	48.9% (45.1%; 53.1%)	42.4% (38.5%; 46.7%)	39.7% (35.8%; 44.1%)	25.3% (20.4%; 31.2%)
Oropharynx C01;C05.1-C05.9;C09-C10	**All**	5,424	78.3% (77.1%; 79.4%)	66.4% (65.1%; 67.8%)	59.6% (58.2%; 61.1%)	55.0% (53.5%; 56.6%)	50.8% (49.2%; 52.5%)	37.0% (34.5%; 39.7%)
	I	935	94.1% (92.4%; 95.9%)	86.3% (83.7%; 88.9%)	82.8% (79.9%; 85.9%)	79.1% (75.7%; 82.7%)	75.8% (71.9%; 79.9%)	62.5% (53.6%; 72.9%)
	II	783	90.3% (88.0%; 92.6%)	82.8% (79.8%; 85.9%)	74.9% (71.4%; 78.7%)	70.1% (66.2%; 74.3%)	65.5% (61.2%; 70.1%)	46.9% (38.9%; 56.4%)
	III	883	81.6% (79.0%; 84.4%)	71.4% (68.3%; 74.8%)	65.8% (62.3%; 69.5%)	62.3% (58.6%; 66.2%)	57.1% (53.1%; 61.4%)	42.2% (35.9%; 49.7%)
	IV	2,332	67.8% (65.9%; 69.8%)	52.7% (50.6%; 54.9%)	44.8% (42.7%; 47.0%)	40.3% (38.2%; 42.6%)	36.2% (34.0%; 38.5%)	26.4% (23.6%; 29.6%)
	X/NA	543	73.2% (69.4%; 77.2%)	58.9% (54.7%; 63.5%)	51.0% (46.7%; 55.8%)	44.3% (39.9%; 49.3%)	42.1% (37.6%; 47.2%)	26.8% (21.3%; 33.6%)
Nasopharynx C11	**All**	472	85.3% (82.0%; 88.7%)	76.5% (72.5%; 80.7%)	72.7% (68.4%; 77.3%)	70.6% (66.1%; 75.5%)	68.1% (63.3%; 73.3%)	61.4% (54.3%; 69.5%)
	I	29	N<50	N<50	N<50	N<50	N<50	N<50
	II	88	94.3% (89.1%; 99.8%)	91.8% (85.0%; 99.2%)	91.2% (83.6%; 99.4%)	90.6% (82.3%; 99.7%)	91.7% (83.3%; 100.9%)	88.1% (74.2%; 104.6%)
	III	148	92.7% (88.4%; 97.3%)	86.7% (80.9%; 92.9%)	82.7% (76.1%; 89.8%)	80.0% (72.9%; 87.9%)	81.0% (73.7%; 88.9%)	76.4% (65.3%; 89.4%)
	IV	173	76.9% (70.8%; 83.6%)	66.5% (59.6%; 74.2%)	60.7% (53.4%; 68.9%)	57.7% (50.1%; 66.4%)	51.1% (43.0%; 60.6%)	44.6% (35.4%; 56.3%)
	X/NA	34	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	**All**	2,314	66.6% (64.7%; 68.6%)	52.0% (49.9%; 54.2%)	42.7% (40.5%; 44.9%)	37.3% (35.1%; 39.6%)	33.0% (30.8%; 35.4%)	19.0% (15.8%; 22.8%)
	I	121	88.9% (82.9%; 95.3%)	80.5% (72.9%; 88.9%)	70.3% (61.2%; 80.7%)	59.9% (50.0%; 71.9%)	55.8% (45.4%; 68.7%)	36.6% (21.1%; 63.6%)

Net Survival Probability, 2015-2024								
location	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	II	183	78.2% (72.1%; 84.8%)	66.1% (59.1%; 73.9%)	55.2% (47.6%; 63.9%)	53.2% (45.4%; 62.3%)	39.7% (31.5%; 50.1%)	21.7% (10.6%; 44.4%)
	III	326	76.9% (72.2%; 81.9%)	63.5% (58.1%; 69.3%)	56.5% (50.8%; 62.8%)	50.5% (44.5%; 57.2%)	48.0% (41.8%; 55.1%)	26.2% (17.8%; 38.7%)
	IV	1,567	61.8% (59.3%; 64.3%)	45.8% (43.3%; 48.4%)	36.1% (33.6%; 38.7%)	31.0% (28.5%; 33.7%)	27.3% (24.8%; 30.0%)	15.7% (12.3%; 20.0%)
	X/NA	120	61.9% (53.7%; 71.4%)	51.0% (42.6%; 61.2%)	42.9% (34.5%; 53.3%)	36.3% (28.2%; 46.9%)	32.0% (24.1%; 42.6%)	18.3% (9.9%; 33.7%)
Larynx (C32)	**All**	4,624	85.7% (84.6%; 86.8%)	78.7% (77.4%; 80.1%)	73.2% (71.6%; 74.8%)	68.5% (66.7%; 70.3%)	65.2% (63.3%; 67.2%)	46.7% (40.9%; 53.3%)
	I	1,557	97.7% (96.6%; 98.9%)	96.1% (94.4%; 97.8%)	92.1% (89.9%; 94.5%)	89.0% (86.0%; 92.1%)	86.2% (82.7%; 89.8%)	68.0% (55.8%; 82.7%)
	II	729	91.0% (88.6%; 93.5%)	82.8% (79.5%; 86.2%)	77.3% (73.5%; 81.2%)	71.9% (67.7%; 76.4%)	67.7% (62.9%; 72.8%)	48.2% (33.2%; 70.0%)
	III	732	80.8% (77.8%; 83.9%)	71.6% (68.1%; 75.3%)	65.7% (61.8%; 69.8%)	59.7% (55.5%; 64.3%)	56.5% (52.0%; 61.4%)	40.2% (33.3%; 48.5%)
	IV	1,143	70.4% (67.7%; 73.2%)	57.5% (54.5%; 60.7%)	49.9% (46.8%; 53.2%)	44.3% (41.1%; 47.7%)	40.4% (37.0%; 44.0%)	24.2% (19.6%; 29.9%)
	X/NA	463	82.1% (78.3%; 86.0%)	77.6% (73.3%; 82.1%)	72.3% (67.4%; 77.6%)	67.8% (62.4%; 73.7%)	65.4% (59.6%; 71.8%)	44.6% (32.9%; 60.4%)
Nasal cavity and paranasal sinuses (C30-C31)	**All**	979	81.6% (78.9%; 84.3%)	69.2% (66.0%; 72.5%)	63.0% (59.5%; 66.7%)	59.2% (55.4%; 63.2%)	58.9% (54.9%; 63.1%)	51.4% (43.9%; 60.3%)
	I	95	96.5% (91.6%; 101.6%)	85.5% (77.3%; 94.7%)	81.7% (72.2%; 92.3%)	78.3% (67.7%; 90.5%)	80.2% (69.3%; 92.6%)	79.1% (60.3%; 103.6%)
	II	124	97.8% (93.5%; 102.2%)	93.7% (87.4%; 100.4%)	88.0% (79.6%; 97.4%)	87.3% (77.3%; 98.6%)	89.0% (78.2%; 101.3%)	70.3% (36.3%; 136.1%)
	III	109	90.4% (84.1%; 97.2%)	82.0% (73.6%; 91.3%)	70.3% (59.9%; 82.6%)	66.6% (55.3%; 80.3%)	66.7% (54.9%; 81.1%)	38.7% (20.6%; 72.8%)
	IV	334	67.2% (62.1%; 72.7%)	51.6% (46.1%; 57.7%)	42.9% (37.4%; 49.3%)	41.5% (35.8%; 48.0%)	39.8% (33.9%; 46.6%)	28.4% (20.3%; 39.9%)
	X/NA	319	82.7% (78.3%; 87.4%)	68.8% (63.3%; 74.8%)	65.7% (59.8%; 72.1%)	58.9% (52.5%; 66.1%)	57.7% (51.1%; 65.2%)	56.5% (46.7%; 68.4%)
Salivary glands (C07-C08)	**All**	768	87.1% (84.4%; 90.0%)	77.0% (73.5%; 80.6%)	71.7% (67.7%; 76.0%)	68.7% (64.3%; 73.4%)	63.9% (58.3%; 70.1%)	57.3% (47.4%; 69.4%)
	I	86	96.4% (92.0%; 101.1%)	97.5% (91.3%; 104.0%)	96.6% (88.6%; 105.3%)	97.4% (87.2%; 108.7%)	92.2% (74.9%; 113.5%)	62.9% (26.5%; 149.6%)
	II	113	97.3% (92.9%; 101.9%)	92.0% (85.4%; 99.1%)	88.3% (80.2%; 97.3%)	88.4% (79.5%; 98.3%)	88.6% (78.4%; 100.2%)	92.7% (75.4%; 113.9%)
	III	86	87.8% (80.3%; 96.0%)	83.1% (73.2%; 94.4%)	73.8% (61.0%; 89.2%)	72.3% (58.4%; 89.4%)	59.3% (40.5%; 86.7%)	39.0% (19.6%; 77.6%)
	IV	221	69.5% (63.1%; 76.4%)	52.1% (45.2%; 60.1%)	47.7% (40.4%; 56.3%)	37.8% (30.1%; 47.4%)	32.8% (24.7%; 43.6%)	FU<10y
	X/NA	262	93.0% (89.3%; 96.9%)	82.6% (77.1%; 88.4%)	75.7% (69.5%; 82.5%)	74.5% (67.8%; 81.8%)	71.2% (63.4%; 80.0%)	67.5% (57.0%; 79.9%)

Net Survival Probability, 2015-2024								
location	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Other and ill-defined sites (C14)	**All**	113	56.4% (47.8%; 66.6%)	46.7% (38.1%; 57.3%)	40.5% (31.9%; 51.3%)	33.5% (25.2%; 44.4%)	34.1% (25.7%; 45.3%)	18.1% (10.2%; 32.2%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	112	56.0% (47.3%; 66.2%)	46.2% (37.6%; 56.9%)	39.9% (31.3%; 50.8%)	32.8% (24.5%; 43.7%)	33.4% (25.0%; 44.6%)	18.5% (10.4%; 32.8%)
Females								
Head & Neck (C00-C14, C30-C32)	**All**	7,187	81.0% (80.1%; 82.0%)	72.5% (71.4%; 73.7%)	67.9% (66.7%; 69.1%)	64.3% (63.0%; 65.7%)	61.4% (60.0%; 62.9%)	50.2% (47.0%; 53.5%)
	I	1,542	95.6% (94.3%; 96.8%)	93.1% (91.4%; 94.7%)	90.2% (88.1%; 92.3%)	87.1% (84.6%; 89.6%)	86.0% (83.3%; 88.8%)	70.2% (58.3%; 84.4%)
	II	1,148	92.3% (90.6%; 94.1%)	85.7% (83.3%; 88.1%)	81.6% (78.8%; 84.4%)	76.9% (73.7%; 80.3%)	74.3% (70.7%; 78.1%)	58.8% (51.2%; 67.5%)
	III	1,050	81.4% (78.9%; 84.0%)	72.6% (69.7%; 75.6%)	66.2% (63.0%; 69.5%)	62.3% (58.9%; 65.9%)	58.4% (54.7%; 62.3%)	49.9% (43.7%; 57.0%)
	IV	2,492	65.4% (63.5%; 67.3%)	51.9% (49.9%; 54.0%)	46.1% (44.0%; 48.3%)	42.8% (40.7%; 45.0%)	39.0% (36.8%; 41.4%)	28.3% (25.1%; 31.9%)
	X/NA	1,173	82.9% (80.6%; 85.2%)	75.3% (72.6%; 78.1%)	70.9% (67.9%; 74.0%)	66.4% (63.1%; 69.8%)	63.8% (60.3%; 67.5%)	56.0% (50.4%; 62.1%)
Lip (C00)	**All**	168	94.2% (89.4%; 99.2%)	89.2% (82.5%; 96.4%)	86.6% (78.3%; 95.8%)	84.1% (74.3%; 95.1%)	83.7% (72.4%; 96.7%)	87.5% (48.9%; 156.7%)
	I	77	98.1% (93.0%; 103.4%)	101.7% (95.2%; 108.6%)	98.4% (87.8%; 110.1%)	95.2% (82.6%; 109.7%)	100.1% (86.9%; 115.4%)	41.5% (11.8%; 146.1%)
	II	26	N<50	N<50	N<50	N<50	N<50	N<50
	III	9	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	47	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	**All**	2,523	80.5% (78.8%; 82.1%)	70.2% (68.2%; 72.2%)	66.1% (64.0%; 68.3%)	62.7% (60.4%; 65.1%)	60.2% (57.8%; 62.8%)	57.5% (53.5%; 61.9%)
	I	555	96.0% (93.9%; 98.1%)	91.6% (88.8%; 94.6%)	89.7% (86.3%; 93.2%)	86.3% (82.2%; 90.5%)	83.8% (79.3%; 88.6%)	75.9% (67.4%; 85.5%)
	II	435	90.7% (87.5%; 93.9%)	84.5% (80.4%; 88.8%)	78.9% (74.0%; 84.2%)	75.2% (69.5%; 81.4%)	72.4% (65.9%; 79.5%)	61.7% (51.4%; 74.0%)

Net Survival Probability, 2015-2024								
location	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	III	334	84.1% (80.0%; 88.5%)	72.9% (67.9%; 78.4%)	67.9% (62.4%; 74.0%)	61.5% (55.3%; 68.2%)	61.0% (54.6%; 68.1%)	68.2% (57.7%; 80.5%)
	IV	887	63.6% (60.4%; 67.0%)	47.8% (44.5%; 51.5%)	43.6% (40.2%; 47.3%)	41.4% (37.8%; 45.3%)	37.8% (34.0%; 41.9%)	31.0% (25.3%; 37.9%)
	X/NA	362	82.8% (78.6%; 87.1%)	73.2% (68.3%; 78.5%)	67.7% (62.3%; 73.6%)	64.7% (59.0%; 71.0%)	62.7% (56.6%; 69.5%)	68.6% (59.0%; 79.8%)
Pharynx (C01, C05.1-C05.9, C09-C13)	**All**	2,698	77.5% (75.9%; 79.2%)	68.2% (66.4%; 70.1%)	62.9% (60.9%; 64.9%)	58.5% (56.4%; 60.6%)	54.8% (52.6%; 57.1%)	39.2% (35.3%; 43.6%)
	I	443	92.6% (89.9%; 95.3%)	89.0% (85.7%; 92.5%)	84.0% (79.9%; 88.2%)	79.7% (75.1%; 84.6%)	77.3% (72.2%; 82.8%)	54.7% (33.7%; 88.8%)
	II	433	91.5% (88.7%; 94.4%)	82.9% (79.1%; 86.9%)	80.3% (76.1%; 84.7%)	74.0% (69.2%; 79.1%)	71.5% (66.5%; 77.0%)	48.2% (38.9%; 59.8%)
	III	463	79.3% (75.5%; 83.3%)	70.7% (66.4%; 75.3%)	65.3% (60.7%; 70.2%)	61.4% (56.6%; 66.7%)	56.8% (51.6%; 62.5%)	42.5% (34.7%; 52.1%)
	IV	1,140	65.9% (63.1%; 68.8%)	53.4% (50.5%; 56.5%)	46.2% (43.2%; 49.4%)	42.5% (39.4%; 45.7%)	38.0% (34.9%; 41.4%)	28.5% (24.6%; 33.1%)
	X/NA	264	75.8% (70.7%; 81.3%)	68.1% (62.5%; 74.3%)	65.0% (59.1%; 71.5%)	57.5% (51.2%; 64.6%)	55.6% (49.1%; 62.9%)	34.7% (26.2%; 46.1%)
Oropharynx C01;C05.1-C05.9;C09-C10	**All**	2,075	79.3% (77.5%; 81.1%)	69.7% (67.6%; 71.8%)	65.1% (62.9%; 67.3%)	61.0% (58.7%; 63.5%)	57.6% (55.1%; 60.2%)	39.6% (34.9%; 44.9%)
	I	396	93.1% (90.4%; 95.9%)	88.9% (85.4%; 92.6%)	84.7% (80.5%; 89.2%)	81.3% (76.5%; 86.4%)	79.3% (74.0%; 85.0%)	52.6% (30.4%; 91.0%)
	II	329	91.9% (88.7%; 95.2%)	82.8% (78.5%; 87.4%)	79.7% (74.9%; 84.9%)	73.3% (67.8%; 79.3%)	71.3% (65.5%; 77.7%)	40.1% (29.3%; 54.7%)
	III	336	80.5% (76.1%; 85.1%)	71.8% (66.8%; 77.1%)	68.4% (63.1%; 74.2%)	65.2% (59.6%; 71.4%)	60.0% (53.9%; 66.8%)	41.8% (32.2%; 54.3%)
	IV	807	67.4% (64.2%; 70.8%)	54.1% (50.6%; 57.8%)	47.3% (43.7%; 51.1%)	43.7% (40.1%; 47.6%)	39.5% (35.9%; 43.6%)	29.5% (24.9%; 34.9%)
	X/NA	229	77.2% (71.8%; 83.0%)	69.6% (63.6%; 76.2%)	67.2% (61.0%; 74.1%)	61.8% (55.0%; 69.4%)	60.6% (53.6%; 68.4%)	39.4% (29.7%; 52.4%)
Nasopharynx C11	**All**	191	86.9% (82.1%; 92.0%)	82.6% (77.1%; 88.4%)	78.8% (72.8%; 85.3%)	76.4% (70.0%; 83.4%)	75.3% (68.6%; 82.6%)	67.6% (56.7%; 80.6%)
	I	10	N<50	N<50	N<50	N<50	N<50	N<50
	II	52	96.6% (91.5%; 102.1%)	95.8% (89.4%; 102.6%)	92.2% (83.9%; 101.3%)	87.6% (77.3%; 99.2%)	88.2% (77.9%; 99.9%)	82.3% (63.6%; 106.5%)
	III	52	86.7% (77.7%; 96.8%)	81.1% (70.7%; 92.9%)	79.1% (68.3%; 91.6%)	77.0% (65.7%; 90.3%)	74.2% (61.9%; 88.9%)	77.8% (64.9%; 93.2%)
	IV	66	79.2% (69.9%; 89.8%)	73.4% (63.3%; 85.2%)	71.9% (61.4%; 84.2%)	72.5% (61.9%; 84.9%)	70.7% (59.5%; 83.9%)	57.3% (41.6%; 78.8%)
	X/NA	11	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024								
location	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Hypopharynx C12-C13	**All**	462	65.6% (61.3%; 70.2%)	55.3% (50.8%; 60.3%)	45.7% (41.1%; 50.9%)	38.1% (33.5%; 43.4%)	31.7% (27.1%; 37.1%)	25.4% (20.1%; 32.1%)
	I	39	N<50	N<50	N<50	N<50	N<50	N<50
	II	54	84.3% (74.6%; 95.3%)	69.7% (57.9%; 84.0%)	70.6% (58.7%; 85.0%)	64.3% (51.4%; 80.3%)	56.5% (43.0%; 74.2%)	54.8% (39.3%; 76.5%)
	III	75	69.1% (59.2%; 80.6%)	59.0% (48.5%; 71.7%)	42.1% (31.8%; 55.8%)	34.4% (24.4%; 48.4%)	31.0% (21.0%; 45.7%)	22.8% (12.4%; 42.0%)
	IV	270	58.1% (52.4%; 64.4%)	46.8% (40.9%; 53.4%)	36.6% (30.9%; 43.3%)	31.3% (25.8%; 38.1%)	24.9% (19.5%; 31.8%)	18.4% (12.7%; 26.8%)
	X/NA	24	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	**All**	905	85.1% (82.7%; 87.6%)	77.8% (74.9%; 80.8%)	70.9% (67.6%; 74.3%)	66.4% (62.7%; 70.2%)	63.1% (59.2%; 67.2%)	45.7% (38.8%; 53.9%)
	I	280	96.5% (93.7%; 99.4%)	95.1% (91.5%; 98.9%)	92.6% (88.1%; 97.4%)	90.1% (84.5%; 96.0%)	91.1% (84.9%; 97.7%)	77.4% (61.5%; 97.5%)
	II	139	91.7% (86.9%; 96.7%)	82.0% (75.3%; 89.3%)	73.0% (65.2%; 81.7%)	65.2% (56.7%; 75.1%)	60.7% (51.7%; 71.3%)	49.9% (38.2%; 65.2%)
	III	165	79.5% (73.2%; 86.4%)	72.8% (65.8%; 80.6%)	62.1% (54.2%; 71.1%)	59.9% (51.7%; 69.4%)	51.5% (42.6%; 62.3%)	37.5% (24.6%; 56.9%)
	IV	232	70.9% (65.2%; 77.2%)	57.1% (50.8%; 64.1%)	49.8% (43.3%; 57.2%)	44.3% (37.8%; 52.0%)	41.9% (35.2%; 50.0%)	15.1% (7.5%; 30.3%)
	X/NA	90	84.5% (77.0%; 92.7%)	78.4% (69.7%; 88.2%)	69.0% (59.1%; 80.4%)	61.6% (50.7%; 74.9%)	55.2% (44.0%; 69.3%)	33.5% (22.1%; 50.6%)
Nasal cavity and paranasal sinuses (C30-C31)	**All**	415	81.8% (77.9%; 86.0%)	74.1% (69.5%; 79.1%)	69.4% (64.3%; 74.9%)	67.0% (61.6%; 72.9%)	63.5% (57.6%; 70.1%)	48.2% (39.0%; 59.6%)
	I	64	95.1% (89.3%; 101.4%)	96.7% (90.7%; 103.0%)	93.0% (84.6%; 102.4%)	90.7% (80.7%; 102.0%)	92.6% (82.4%; 104.1%)	87.4% (71.2%; 107.4%)
	II	29	N<50	N<50	N<50	N<50	N<50	N<50
	III	34	N<50	N<50	N<50	N<50	N<50	N<50
	IV	123	61.8% (53.4%; 71.6%)	51.1% (42.1%; 62.1%)	44.0% (34.8%; 55.6%)	40.0% (30.8%; 52.0%)	37.3% (27.7%; 50.4%)	33.2% (22.2%; 49.7%)
	X/NA	165	86.7% (81.2%; 92.5%)	77.2% (70.4%; 84.7%)	75.2% (67.9%; 83.3%)	72.5% (64.6%; 81.5%)	66.3% (57.3%; 76.6%)	40.5% (28.8%; 56.9%)
Salivary glands (C07-C08)	**All**	602	90.6% (88.0%; 93.3%)	88.1% (85.0%; 91.4%)	86.8% (83.2%; 90.5%)	84.8% (80.6%; 89.3%)	84.1% (79.3%; 89.1%)	67.7% (53.9%; 85.1%)
	I	138	99.1% (97.0%; 101.2%)	99.2% (96.0%; 102.5%)	98.8% (94.7%; 103.1%)	98.3% (93.1%; 103.8%)	98.9% (92.1%; 106.1%)	77.9% (33.0%; 183.9%)
	II	97	99.3% (97.3%; 101.3%)	102.9% (100.0%; 105.8%)	103.7% (98.7%; 108.9%)	103.1% (95.5%; 111.2%)	105.6% (96.7%; 115.4%)	69.1% (35.8%; 133.3%)
	III	48	N<50	N<50	N<50	N<50	N<50	N<50

location	cStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	112	67.8% (59.1%; 77.7%)	58.0% (48.6%; 69.2%)	58.5% (48.7%; 70.4%)	54.8% (44.1%; 67.9%)	52.0% (40.5%; 66.7%)	33.3% (19.5%; 57.0%)
	X/NA	208	93.1% (89.0%; 97.3%)	91.3% (86.3%; 96.5%)	88.1% (82.2%; 94.5%)	84.8% (77.6%; 92.7%)	85.0% (77.4%; 93.4%)	77.9% (64.1%; 94.8%)
Other and ill-defined sites (C14)	**All**	44	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	44	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation. Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.3. Head & Neck cancer survival by sub-location, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
location	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	25,805	80.4% (79.9%; 80.9%)	70.6% (70.0%; 71.3%)	64.7% (64.0%; 65.4%)	60.4% (59.7%; 61.2%)	57.0% (56.2%; 57.8%)	44.0% (42.2%; 45.8%)
Males								
Head & Neck (C00-C14, C30-C32)	**All**	18,618	80.2% (79.5%; 80.8%)	69.9% (69.2%; 70.6%)	63.5% (62.7%; 64.3%)	58.9% (58.1%; 59.8%)	55.3% (54.4%; 56.3%)	41.7% (39.6%; 43.9%)
	I	2,683	98.0% (97.2%; 98.8%)	94.3% (93.0%; 95.6%)	90.4% (88.7%; 92.1%)	86.4% (84.4%; 88.5%)	83.4% (81.0%; 85.9%)	72.9% (66.1%; 80.4%)
	II	1,159	93.9% (92.3%; 95.6%)	86.4% (84.0%; 88.8%)	79.9% (77.1%; 82.8%)	74.5% (71.3%; 77.9%)	69.4% (65.8%; 73.2%)	54.4% (41.9%; 70.6%)
	III	1,092	90.1% (88.1%; 92.1%)	80.5% (77.8%; 83.2%)	74.7% (71.7%; 77.8%)	70.1% (66.9%; 73.6%)	66.4% (62.8%; 70.3%)	52.5% (46.0%; 59.8%)
	IV	2,522	80.9% (79.3%; 82.6%)	63.8% (61.8%; 65.8%)	55.2% (53.1%; 57.4%)	48.8% (46.5%; 51.1%)	43.9% (41.6%; 46.4%)	31.5% (28.0%; 35.4%)
	X/NA	11,660	73.6% (72.7%; 74.4%)	62.7% (61.7%; 63.6%)	55.9% (54.9%; 56.9%)	51.4% (50.4%; 52.5%)	47.9% (46.8%; 49.1%)	33.8% (31.5%; 36.2%)
Lip (C00)	**All**	317	94.0% (90.5%; 97.6%)	90.2% (85.5%; 95.2%)	87.9% (82.1%; 94.2%)	87.0% (80.3%; 94.3%)	86.2% (78.6%; 94.5%)	74.5% (53.4%; 104.1%)
	I	185	99.7% (96.5%; 103.1%)	99.0% (94.0%; 104.3%)	99.3% (92.5%; 106.6%)	97.7% (89.1%; 107.1%)	96.6% (86.5%; 107.7%)	79.9% (48.2%; 132.5%)
	II	57	96.1% (89.1%; 103.6%)	93.2% (84.1%; 103.2%)	87.0% (75.1%; 100.8%)	89.8% (77.5%; 104.0%)	92.5% (79.0%; 108.4%)	85.4% (55.1%; 132.5%)
	III	21	N<50	N<50	N<50	N<50	N<50	N<50
	IV	11	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	**All**	4,339	80.4% (79.2%; 81.7%)	69.9% (68.4%; 71.4%)	63.0% (61.4%; 64.7%)	57.8% (56.1%; 59.6%)	53.6% (51.8%; 55.5%)	42.3% (39.3%; 45.5%)
	I	951	98.8% (97.7%; 100.0%)	94.2% (92.2%; 96.3%)	89.2% (86.6%; 91.9%)	84.4% (81.2%; 87.8%)	80.6% (76.8%; 84.6%)	69.2% (63.0%; 76.1%)
	II	574	92.3% (89.8%; 94.8%)	86.6% (83.3%; 89.9%)	80.0% (76.1%; 84.1%)	72.5% (67.9%; 77.4%)	65.9% (60.8%; 71.4%)	50.3% (42.0%; 60.4%)
	III	553	88.5% (85.7%; 91.5%)	78.6% (74.9%; 82.4%)	71.6% (67.4%; 76.0%)	66.5% (62.0%; 71.4%)	62.4% (57.4%; 67.8%)	49.6% (41.3%; 59.5%)
	IV	1,098	80.9% (78.5%; 83.4%)	65.4% (62.4%; 68.5%)	56.6% (53.4%; 59.9%)	49.8% (46.4%; 53.3%)	44.5% (41.0%; 48.3%)	33.7% (28.0%; 40.6%)

location	pStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	1,219	56.4% (53.6%; 59.4%)	42.2% (39.3%; 45.2%)	35.3% (32.5%; 38.4%)	31.7% (28.9%; 34.8%)	29.2% (26.4%; 32.4%)	20.0% (15.9%; 25.0%)
Pharynx (C01, C05.1-C05.9, C09-C13)	**All**	8,062	75.5% (74.5%; 76.5%)	63.2% (62.0%; 64.3%)	55.9% (54.7%; 57.1%)	51.1% (49.9%; 52.4%)	47.0% (45.7%; 48.3%)	33.6% (31.5%; 35.7%)
	I	612	94.6% (92.6%; 96.7%)	86.7% (83.6%; 89.9%)	81.2% (77.5%; 85.0%)	75.4% (71.2%; 79.9%)	72.4% (67.8%; 77.4%)	58.0% (49.2%; 68.4%)
	II	239	92.4% (88.7%; 96.2%)	78.4% (72.9%; 84.4%)	72.0% (65.8%; 78.7%)	66.8% (60.2%; 74.2%)	59.2% (52.0%; 67.4%)	53.3% (43.2%; 65.7%)
	III	210	89.7% (85.4%; 94.3%)	78.3% (72.5%; 84.7%)	75.4% (69.1%; 82.3%)	68.4% (61.4%; 76.2%)	61.0% (53.5%; 69.7%)	54.1% (43.6%; 67.1%)
	IV	591	76.8% (73.3%; 80.4%)	53.9% (49.9%; 58.3%)	45.3% (41.2%; 49.8%)	41.1% (37.0%; 45.8%)	36.0% (31.7%; 40.8%)	26.0% (20.7%; 32.7%)
	X/NA	6,504	72.6% (71.4%; 73.7%)	60.6% (59.4%; 61.9%)	53.1% (51.8%; 54.4%)	48.5% (47.1%; 49.9%)	44.5% (43.1%; 46.0%)	30.1% (27.9%; 32.6%)
Oropharynx C01;C05.1-C05.9;C09-C10	**All**	5,424	78.3% (77.1%; 79.4%)	66.4% (65.1%; 67.8%)	59.6% (58.2%; 61.1%)	55.0% (53.5%; 56.6%)	50.8% (49.2%; 52.5%)	37.0% (34.5%; 39.7%)
	I	556	94.8% (92.7%; 97.0%)	87.4% (84.2%; 90.7%)	82.3% (78.6%; 86.3%)	76.8% (72.5%; 81.4%)	74.5% (69.8%; 79.7%)	60.1% (51.3%; 70.3%)
	II	199	93.0% (89.2%; 97.1%)	79.1% (73.1%; 85.5%)	74.5% (68.0%; 81.7%)	70.6% (63.4%; 78.5%)	63.4% (55.5%; 72.4%)	57.5% (46.1%; 71.7%)
	III	173	91.1% (86.6%; 95.9%)	81.2% (75.1%; 87.9%)	77.9% (71.2%; 85.3%)	72.8% (65.4%; 81.1%)	64.6% (56.5%; 74.0%)	57.3% (45.9%; 71.5%)
	IV	297	80.2% (75.6%; 85.1%)	61.1% (55.5%; 67.3%)	53.0% (47.2%; 59.5%)	49.0% (43.0%; 55.7%)	43.6% (37.4%; 50.8%)	36.4% (29.0%; 45.6%)
	X/NA	4,237	74.8% (73.4%; 76.2%)	62.8% (61.3%; 64.4%)	55.6% (54.0%; 57.3%)	51.0% (49.3%; 52.8%)	47.0% (45.2%; 48.9%)	31.6% (28.7%; 34.7%)
Nasopharynx C11	**All**	472	85.3% (82.0%; 88.7%)	76.5% (72.5%; 80.7%)	72.7% (68.4%; 77.3%)	70.6% (66.1%; 75.5%)	68.1% (63.3%; 73.3%)	61.4% (54.3%; 69.5%)
	I	4	N<50	N<50	N<50	N<50	N<50	N<50
	II	2	N<50	N<50	N<50	N<50	N<50	N<50
	III	1	N<50	N<50	N<50	N<50	N<50	N<50
	IV	8	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	457	86.3% (83.0%; 89.6%)	77.4% (73.4%; 81.6%)	73.5% (69.1%; 78.1%)	71.2% (66.6%; 76.1%)	68.6% (63.7%; 73.8%)	61.6% (54.4%; 69.8%)

Net Survival Probability, 2015-2024								
location	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Hypopharynx C12-C13	**All**	2,314	66.6% (64.7%; 68.6%)	52.0% (49.9%; 54.2%)	42.7% (40.5%; 44.9%)	37.3% (35.1%; 39.6%)	33.0% (30.8%; 35.4%)	19.0% (15.8%; 22.8%)
	I	57	95.0% (88.5%; 102.0%)	82.4% (71.9%; 94.4%)	73.0% (60.4%; 88.3%)	65.0% (51.3%; 82.3%)	54.5% (40.1%; 74.2%)	25.9% (7.9%; 85.1%)
	II	38	N<50	N<50	N<50	N<50	N<50	N<50
	III	37	N<50	N<50	N<50	N<50	N<50	N<50
	IV	289	74.7% (69.6%; 80.1%)	47.5% (41.9%; 53.9%)	37.7% (32.2%; 44.1%)	33.4% (27.9%; 39.9%)	28.1% (22.6%; 34.8%)	12.2% (6.1%; 24.2%)
	X/NA	1,893	63.8% (61.6%; 66.0%)	51.0% (48.7%; 53.5%)	41.8% (39.4%; 44.3%)	36.7% (34.3%; 39.3%)	32.9% (30.5%; 35.5%)	19.0% (15.6%; 23.2%)
Larynx (C32)	**All**	4,624	85.7% (84.6%; 86.8%)	78.7% (77.4%; 80.1%)	73.2% (71.6%; 74.8%)	68.5% (66.7%; 70.3%)	65.2% (63.3%; 67.2%)	46.7% (40.9%; 53.3%)
	I	786	98.9% (97.5%; 100.4%)	97.9% (95.7%; 100.1%)	95.0% (92.0%; 98.2%)	91.8% (87.7%; 96.0%)	89.1% (84.4%; 94.1%)	76.7% (57.1%; 103.0%)
	II	97	92.7% (87.0%; 98.9%)	84.5% (75.7%; 94.3%)	73.5% (63.0%; 85.8%)	69.1% (57.6%; 82.8%)	67.6% (55.4%; 82.6%)	26.6% (5.6%; 125.4%)
	III	161	87.4% (82.1%; 93.1%)	82.8% (76.5%; 89.6%)	77.1% (70.0%; 84.9%)	73.2% (65.4%; 81.9%)	71.9% (63.6%; 81.4%)	58.9% (44.7%; 77.7%)
	IV	527	84.2% (80.9%; 87.6%)	69.5% (65.3%; 73.9%)	60.7% (56.2%; 65.6%)	53.2% (48.4%; 58.4%)	49.3% (44.3%; 55.0%)	31.1% (24.8%; 39.1%)
	X/NA	3,053	82.1% (80.6%; 83.6%)	75.0% (73.3%; 76.8%)	69.5% (67.6%; 71.5%)	65.0% (62.8%; 67.3%)	61.5% (59.1%; 63.9%)	42.9% (37.2%; 49.5%)
Nasal cavity and paranasal sinuses (C30-C31)	**All**	979	81.6% (78.9%; 84.3%)	69.2% (66.0%; 72.5%)	63.0% (59.5%; 66.7%)	59.2% (55.4%; 63.2%)	58.9% (54.9%; 63.1%)	51.4% (43.9%; 60.3%)
	I	93	94.9% (89.5%; 100.5%)	91.1% (84.1%; 98.8%)	87.0% (78.1%; 96.9%)	82.1% (71.8%; 93.9%)	83.2% (72.7%; 95.2%)	80.6% (59.4%; 109.3%)
	II	86	99.7% (95.7%; 103.9%)	93.3% (85.9%; 101.3%)	86.3% (76.9%; 96.8%)	88.6% (77.8%; 100.7%)	88.6% (76.7%; 102.4%)	81.1% (57.9%; 113.6%)
	III	72	95.2% (89.4%; 101.5%)	85.4% (76.1%; 95.8%)	79.3% (67.5%; 93.1%)	76.0% (63.4%; 91.0%)	78.7% (65.7%; 94.4%)	45.8% (24.3%; 86.3%)
	IV	154	78.2% (71.5%; 85.5%)	60.6% (52.7%; 69.6%)	55.9% (47.7%; 65.4%)	50.1% (41.3%; 60.8%)	45.5% (36.6%; 56.6%)	25.7% (15.4%; 42.7%)
	X/NA	577	75.8% (72.2%; 79.7%)	62.3% (58.1%; 66.9%)	55.6% (51.1%; 60.6%)	51.8% (47.0%; 57.1%)	51.1% (46.1%; 56.7%)	49.7% (40.0%; 61.6%)
Salivary glands (C07-C08)	**All**	768	87.1% (84.4%; 90.0%)	77.0% (73.5%; 80.6%)	71.7% (67.7%; 76.0%)	68.7% (64.3%; 73.4%)	63.9% (58.3%; 70.1%)	57.3% (47.4%; 69.4%)
	I	105	99.3% (97.4%; 101.2%)	99.2% (95.1%; 103.6%)	99.6% (94.5%; 105.0%)	101.1% (95.5%; 107.2%)	93.8% (81.3%; 108.1%)	100.1% (82.6%; 121.4%)
	II	109	99.8% (96.7%; 103.1%)	94.5% (88.3%; 101.2%)	92.8% (85.5%; 100.8%)	88.3% (79.1%; 98.5%)	86.8% (76.2%; 99.0%)	96.5% (83.3%; 111.8%)

location	pStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	79	100.3% (96.1%; 104.8%)	89.3% (80.0%; 99.7%)	82.4% (70.6%; 96.1%)	85.4% (72.7%; 100.3%)	85.9% (70.1%; 105.2%)	68.1% (43.7%; 106.1%)
	IV	152	88.8% (83.1%; 94.8%)	73.6% (65.8%; 82.4%)	64.1% (55.4%; 74.1%)	53.3% (43.9%; 64.7%)	49.8% (39.4%; 63.0%)	48.4% (32.0%; 73.3%)
	X/NA	323	74.0% (68.9%; 79.5%)	62.1% (56.3%; 68.5%)	56.1% (49.7%; 63.4%)	53.5% (46.5%; 61.5%)	47.1% (38.5%; 57.7%)	32.9% (20.8%; 52.3%)
Other and ill-defined sites (C14)	**All**	113	56.4% (47.8%; 66.6%)	46.7% (38.1%; 57.3%)	40.5% (31.9%; 51.3%)	33.5% (25.2%; 44.4%)	34.1% (25.7%; 45.3%)	18.1% (10.2%; 32.2%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	112	56.0% (47.3%; 66.2%)	46.2% (37.6%; 56.9%)	39.9% (31.3%; 50.8%)	32.8% (24.5%; 43.7%)	33.4% (25.0%; 44.6%)	18.5% (10.4%; 32.8%)
Females								
Head & Neck (C00-C14, C30-C32)	**All**	7,187	81.0% (80.1%; 82.0%)	72.5% (71.4%; 73.7%)	67.9% (66.7%; 69.1%)	64.3% (63.0%; 65.7%)	61.4% (60.0%; 62.9%)	50.2% (47.0%; 53.5%)
	I	1,424	97.2% (96.1%; 98.3%)	95.8% (94.3%; 97.3%)	92.6% (90.6%; 94.7%)	90.2% (87.9%; 92.7%)	88.9% (86.2%; 91.6%)	73.9% (63.4%; 86.2%)
	II	632	97.6% (95.9%; 99.4%)	92.0% (89.2%; 94.8%)	89.0% (85.5%; 92.7%)	86.5% (82.3%; 91.0%)	83.7% (78.6%; 89.1%)	78.5% (66.7%; 92.6%)
	III	467	92.9% (90.2%; 95.7%)	82.1% (78.1%; 86.2%)	75.6% (71.1%; 80.4%)	72.3% (67.4%; 77.5%)	69.1% (63.8%; 74.9%)	63.6% (53.9%; 75.1%)
	IV	934	80.8% (78.1%; 83.5%)	67.1% (63.9%; 70.4%)	60.8% (57.4%; 64.4%)	56.7% (53.2%; 60.6%)	53.1% (49.3%; 57.2%)	41.6% (35.0%; 49.4%)
	X/NA	3,910	71.2% (69.8%; 72.7%)	61.0% (59.4%; 62.7%)	56.0% (54.3%; 57.8%)	51.6% (49.8%; 53.5%)	48.4% (46.5%; 50.3%)	36.9% (34.0%; 40.0%)
Lip (C00)	**All**	168	94.2% (89.4%; 99.2%)	89.2% (82.5%; 96.4%)	86.6% (78.3%; 95.8%)	84.1% (74.3%; 95.1%)	83.7% (72.4%; 96.7%)	87.5% (48.9%; 156.7%)
	I	101	97.7% (92.9%; 102.7%)	97.5% (90.4%; 105.1%)	93.7% (83.7%; 104.9%)	89.8% (77.5%; 104.1%)	90.6% (77.0%; 106.6%)	43.6% (13.6%; 139.3%)
	II	25	N<50	N<50	N<50	N<50	N<50	N<50
	III	7	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	26	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024								
location	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Oral cavity (C02-C05.0, C06)	**All**	2,523	80.5% (78.8%; 82.1%)	70.2% (68.2%; 72.2%)	66.1% (64.0%; 68.3%)	62.7% (60.4%; 65.1%)	60.2% (57.8%; 62.8%)	57.5% (53.5%; 61.9%)
	I	653	96.5% (94.7%; 98.3%)	93.9% (91.5%; 96.4%)	91.0% (88.0%; 94.1%)	88.7% (85.2%; 92.4%)	86.0% (82.0%; 90.2%)	85.3% (78.4%; 92.8%)
	II	353	97.0% (94.6%; 99.6%)	89.9% (85.9%; 94.1%)	87.2% (82.2%; 92.5%)	84.0% (77.9%; 90.7%)	81.2% (73.9%; 89.2%)	87.6% (73.1%; 104.9%)
	III	279	91.9% (88.2%; 95.7%)	78.7% (73.4%; 84.4%)	74.3% (68.4%; 80.6%)	69.5% (63.1%; 76.6%)	67.1% (60.2%; 74.9%)	63.8% (51.9%; 78.5%)
	IV	598	81.4% (78.2%; 84.8%)	65.9% (61.9%; 70.1%)	59.8% (55.5%; 64.3%)	57.0% (52.5%; 61.8%)	53.4% (48.7%; 58.6%)	52.3% (44.3%; 61.6%)
	X/NA	684	51.6% (47.8%; 55.7%)	38.1% (34.4%; 42.3%)	33.9% (30.2%; 38.1%)	29.2% (25.4%; 33.5%)	27.8% (23.9%; 32.3%)	17.7% (12.9%; 24.2%)
Pharynx (C01, C05.1-C05.9, C09-C13)	**All**	2,698	77.5% (75.9%; 79.2%)	68.2% (66.4%; 70.1%)	62.9% (60.9%; 64.9%)	58.5% (56.4%; 60.6%)	54.8% (52.6%; 57.1%)	39.2% (35.3%; 43.6%)
	I	287	96.0% (93.4%; 98.7%)	94.2% (91.0%; 97.6%)	87.8% (83.2%; 92.6%)	84.8% (79.7%; 90.3%)	82.6% (76.9%; 88.7%)	50.0% (31.9%; 78.5%)
	II	105	94.6% (89.9%; 99.5%)	86.4% (79.4%; 94.0%)	85.0% (77.3%; 93.4%)	81.7% (73.1%; 91.3%)	78.8% (69.3%; 89.6%)	67.7% (49.9%; 91.7%)
	III	77	95.3% (90.5%; 100.4%)	90.6% (83.5%; 98.3%)	80.4% (70.7%; 91.3%)	77.4% (67.0%; 89.4%)	71.7% (60.6%; 84.9%)	72.7% (60.6%; 87.3%)
	IV	138	79.2% (72.6%; 86.5%)	65.1% (57.4%; 73.9%)	58.2% (50.1%; 67.6%)	50.6% (42.3%; 60.6%)	45.7% (37.2%; 56.2%)	24.3% (14.7%; 40.2%)
	X/NA	2,117	73.6% (71.7%; 75.5%)	63.2% (61.1%; 65.4%)	58.1% (55.9%; 60.4%)	53.5% (51.1%; 55.9%)	49.7% (47.3%; 52.3%)	35.8% (32.1%; 39.9%)
Oropharynx C01;C05.1-C05.9;C09-C10	**All**	2,075	79.3% (77.5%; 81.1%)	69.7% (67.6%; 71.8%)	65.1% (62.9%; 67.3%)	61.0% (58.7%; 63.5%)	57.6% (55.1%; 60.2%)	39.6% (34.9%; 44.9%)
	I	263	95.9% (93.2%; 98.7%)	93.8% (90.3%; 97.4%)	87.6% (82.9%; 92.7%)	85.3% (80.0%; 91.0%)	82.8% (76.9%; 89.1%)	46.0% (27.7%; 76.5%)
	II	94	96.0% (91.5%; 100.7%)	87.9% (80.8%; 95.7%)	87.4% (79.7%; 95.9%)	83.7% (74.9%; 93.6%)	80.4% (70.5%; 91.8%)	67.6% (48.8%; 93.8%)
	III	69	94.7% (89.3%; 100.4%)	89.0% (81.2%; 97.6%)	82.4% (72.6%; 93.5%)	82.9% (73.0%; 94.0%)	76.8% (65.8%; 89.7%)	77.6% (65.4%; 92.1%)
	IV	93	85.0% (77.8%; 92.9%)	67.1% (57.9%; 77.8%)	63.6% (53.9%; 74.9%)	56.2% (46.2%; 68.5%)	53.4% (43.0%; 66.2%)	30.3% (17.9%; 51.3%)
	X/NA	1,573	74.5% (72.4%; 76.8%)	63.9% (61.5%; 66.5%)	59.2% (56.7%; 61.9%)	54.7% (52.0%; 57.6%)	51.2% (48.4%; 54.3%)	35.1% (30.7%; 40.0%)
Nasopharynx C11	**All**	191	86.9% (82.1%; 92.0%)	82.6% (77.1%; 88.4%)	78.8% (72.8%; 85.3%)	76.4% (70.0%; 83.4%)	75.3% (68.6%; 82.6%)	67.6% (56.7%; 80.6%)

location	pStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	I	4	N<50	N<50	N<50	N<50	N<50	N<50
	II	5	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	6	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	174	86.1% (81.0%; 91.6%)	81.3% (75.4%; 87.6%)	79.9% (73.7%; 86.5%)	78.0% (71.5%; 85.1%)	77.6% (70.9%; 85.0%)	69.1% (57.6%; 82.9%)
Hypopharynx C12-C13	**All**	462	65.6% (61.3%; 70.2%)	55.3% (50.8%; 60.3%)	45.7% (41.1%; 50.9%)	38.1% (33.5%; 43.4%)	31.7% (27.1%; 37.1%)	25.4% (20.1%; 32.1%)
	I	22	N<50	N<50	N<50	N<50	N<50	N<50
	II	6	N<50	N<50	N<50	N<50	N<50	N<50
	III	6	N<50	N<50	N<50	N<50	N<50	N<50
	IV	39	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	389	63.3% (58.6%; 68.4%)	52.0% (47.0%; 57.4%)	42.7% (37.7%; 48.3%)	35.7% (30.8%; 41.4%)	29.6% (24.7%; 35.4%)	24.0% (18.4%; 31.2%)
Larynx (C32)	**All**	905	85.1% (82.7%; 87.6%)	77.8% (74.9%; 80.8%)	70.9% (67.6%; 74.3%)	66.4% (62.7%; 70.2%)	63.1% (59.2%; 67.2%)	45.7% (38.8%; 53.9%)
	I	158	96.3% (92.6%; 100.2%)	96.5% (92.1%; 101.1%)	95.6% (90.2%; 101.2%)	91.4% (84.2%; 99.2%)	91.0% (82.9%; 99.8%)	62.4% (43.4%; 89.7%)
	II	18	N<50	N<50	N<50	N<50	N<50	N<50
	III	35	N<50	N<50	N<50	N<50	N<50	N<50
	IV	64	80.7% (71.1%; 91.5%)	68.8% (57.9%; 81.8%)	62.4% (51.0%; 76.4%)	55.1% (43.3%; 70.3%)	53.2% (40.8%; 69.3%)	8.8% (2.1%; 36.2%)
	X/NA	630	81.7% (78.6%; 85.0%)	73.1% (69.5%; 77.0%)	65.2% (61.2%; 69.5%)	60.9% (56.6%; 65.6%)	57.1% (52.5%; 62.2%)	44.2% (37.0%; 52.9%)
Nasal cavity and paranasal sinuses (C30-C31)	**All**	415	81.8% (77.9%; 86.0%)	74.1% (69.5%; 79.1%)	69.4% (64.3%; 74.9%)	67.0% (61.6%; 72.9%)	63.5% (57.6%; 70.1%)	48.2% (39.0%; 59.6%)
	I	56	97.7% (93.0%; 102.7%)	99.0% (94.2%; 104.1%)	97.7% (90.8%; 105.3%)	96.7% (88.4%; 105.8%)	98.1% (89.6%; 107.3%)	82.5% (60.4%; 112.7%)
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	20	N<50	N<50	N<50	N<50	N<50	N<50

location	pStage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IV	47	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	268	76.8% (71.5%; 82.4%)	68.1% (62.1%; 74.7%)	65.8% (59.4%; 72.8%)	63.0% (56.3%; 70.5%)	58.2% (51.0%; 66.5%)	43.4% (33.6%; 56.0%)
Salivary glands (C07-C08)	**All**	602	90.6% (88.0%; 93.3%)	88.1% (85.0%; 91.4%)	86.8% (83.2%; 90.5%)	84.8% (80.6%; 89.3%)	84.1% (79.3%; 89.1%)	67.7% (53.9%; 85.1%)
	I	181	99.9% (98.9%; 101.0%)	101.2% (99.6%; 102.8%)	100.7% (97.8%; 103.7%)	101.2% (97.5%; 105.0%)	104.2% (100.4%; 108.2%)	88.5% (54.8%; 143.0%)
	II	109	100.4% (98.4%; 102.4%)	101.0% (97.4%; 104.7%)	100.7% (95.6%; 106.0%)	98.3% (91.0%; 106.3%)	96.4% (87.3%; 106.6%)	69.4% (41.7%; 115.6%)
	III	50	90.3% (81.1%; 100.4%)	88.7% (78.7%; 100.0%)	90.6% (79.6%; 103.1%)	94.1% (82.7%; 107.1%)	91.9% (78.0%; 108.3%)	76.0% (54.2%; 106.5%)
	IV	80	81.6% (73.1%; 91.0%)	77.8% (68.4%; 88.5%)	71.7% (61.2%; 83.9%)	66.0% (54.9%; 79.5%)	63.8% (52.3%; 77.9%)	50.3% (35.8%; 70.7%)
	X/NA	182	78.4% (72.0%; 85.3%)	71.3% (64.0%; 79.6%)	70.2% (62.2%; 79.3%)	66.2% (57.1%; 76.9%)	63.7% (53.8%; 75.5%)	51.8% (35.6%; 75.2%)
Other and ill-defined sites (C14)	**All**	44	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	44	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2.4. Head & Neck cancer survival by sub-location, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
location	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	25,805	80.4% (79.9%; 80.9%)	70.6% (70.0%; 71.3%)	64.7% (64.0%; 65.4%)	60.4% (59.7%; 61.2%)	57.0% (56.2%; 57.8%)	44.0% (42.2%; 45.8%)
Males								
Head & Neck (C00-C14, C30-C32)	**All**	18,618	80.2% (79.5%; 80.8%)	69.9% (69.2%; 70.6%)	63.5% (62.7%; 64.3%)	58.9% (58.1%; 59.8%)	55.3% (54.4%; 56.3%)	41.7% (39.6%; 43.9%)
	I	4,270	96.7% (95.9%; 97.4%)	92.7% (91.6%; 93.8%)	88.8% (87.5%; 90.2%)	85.0% (83.3%; 86.8%)	81.9% (79.9%; 83.9%)	66.8% (60.5%; 73.8%)
	II	2,697	90.5% (89.2%; 91.7%)	83.1% (81.4%; 84.8%)	76.3% (74.4%; 78.3%)	71.6% (69.5%; 73.9%)	66.7% (64.2%; 69.2%)	50.6% (43.2%; 59.2%)
	III	3,007	83.0% (81.6%; 84.5%)	73.7% (71.9%; 75.4%)	67.7% (65.7%; 69.7%)	63.1% (61.0%; 65.2%)	59.3% (57.0%; 61.7%)	44.8% (41.0%; 49.0%)
	IV	49	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	6,814	71.2% (70.1%; 72.3%)	56.4% (55.1%; 57.6%)	47.8% (46.6%; 49.2%)	42.7% (41.4%; 44.0%)	38.6% (37.2%; 40.0%)	26.0% (24.1%; 28.1%)
	IVC	899	41.0% (37.9%; 44.4%)	22.6% (19.9%; 25.6%)	16.2% (13.8%; 19.0%)	12.1% (9.9%; 14.9%)	10.3% (8.2%; 13.0%)	6.6% (4.5%; 9.8%)
	X/NA	1,528	71.4% (69.1%; 73.8%)	59.8% (57.2%; 62.6%)	53.8% (51.1%; 56.7%)	48.7% (45.8%; 51.8%)	46.9% (43.9%; 50.2%)	34.9% (30.2%; 40.5%)
Lip (C00)	**All**	317	94.0% (90.5%; 97.6%)	90.2% (85.5%; 95.2%)	87.9% (82.1%; 94.2%)	87.0% (80.3%; 94.3%)	86.2% (78.6%; 94.5%)	74.5% (53.4%; 104.1%)
	I	194	98.4% (94.9%; 102.2%)	97.5% (92.3%; 103.0%)	97.0% (90.0%; 104.6%)	95.7% (87.1%; 105.2%)	94.1% (84.1%; 105.2%)	76.7% (46.9%; 125.4%)
	II	57	94.3% (86.7%; 102.6%)	91.4% (81.9%; 102.0%)	85.2% (73.0%; 99.4%)	87.9% (75.4%; 102.6%)	90.7% (76.9%; 107.0%)	83.6% (53.6%; 130.5%)
	III	25	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	13	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	3	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	25	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	**All**	4,339	80.4% (79.2%; 81.7%)	69.9% (68.4%; 71.4%)	63.0% (61.4%; 64.7%)	57.8% (56.1%; 59.6%)	53.6% (51.8%; 55.5%)	42.3% (39.3%; 45.5%)
	I	1,013	97.7% (96.4%; 99.0%)	92.5% (90.5%; 94.7%)	87.8% (85.2%; 90.5%)	83.1% (79.9%; 86.4%)	79.0% (75.3%; 82.9%)	68.8% (62.8%; 75.3%)
	II	651	89.5% (87.0%; 92.2%)	83.3% (80.1%; 86.7%)	76.4% (72.6%; 80.4%)	69.5% (65.2%; 74.2%)	62.7% (57.9%; 67.8%)	48.7% (40.9%; 58.0%)

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	684	82.8% (79.9%; 85.9%)	73.0% (69.4%; 76.7%)	65.9% (62.0%; 70.1%)	61.1% (56.9%; 65.6%)	58.1% (53.6%; 63.0%)	48.9% (41.1%; 58.1%)
	IV	1	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,758	71.2% (69.0%; 73.4%)	55.4% (53.0%; 57.9%)	47.1% (44.6%; 49.7%)	41.5% (39.0%; 44.2%)	37.2% (34.6%; 40.1%)	25.4% (21.5%; 30.0%)
	IVC	126	36.1% (28.5%; 45.7%)	22.3% (15.8%; 31.4%)	16.5% (10.5%; 25.8%)	13.4% (8.0%; 22.4%)	12.1% (6.9%; 21.2%)	5.6% (2.0%; 15.5%)
	X/NA	163	60.6% (53.3%; 69.0%)	48.0% (40.4%; 56.9%)	42.3% (34.6%; 51.7%)	37.2% (29.5%; 46.8%)	36.0% (28.1%; 46.0%)	22.7% (11.9%; 43.0%)
Pharynx (C01, C05.1-C05.9, C09-C13)	**All**	8,062	75.5% (74.5%; 76.5%)	63.2% (62.0%; 64.3%)	55.9% (54.7%; 57.1%)	51.1% (49.9%; 52.4%)	47.0% (45.7%; 48.3%)	33.6% (31.5%; 35.7%)
	I	1,193	93.4% (91.8%; 95.1%)	86.1% (83.9%; 88.5%)	81.2% (78.5%; 83.9%)	76.4% (73.3%; 79.6%)	72.7% (69.3%; 76.3%)	55.6% (48.2%; 64.1%)
	II	1,054	89.4% (87.3%; 91.5%)	80.6% (78.0%; 83.4%)	72.8% (69.7%; 76.1%)	69.0% (65.6%; 72.5%)	63.3% (59.5%; 67.2%)	48.5% (41.9%; 56.0%)
	III	1,385	82.1% (80.0%; 84.2%)	72.0% (69.4%; 74.6%)	66.8% (64.1%; 69.7%)	62.0% (59.1%; 65.1%)	57.6% (54.4%; 60.9%)	43.1% (38.1%; 48.7%)
	IV	48	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	3,503	69.9% (68.3%; 71.5%)	55.1% (53.4%; 56.9%)	46.2% (44.4%; 48.0%)	41.5% (39.7%; 43.4%)	37.4% (35.6%; 39.3%)	25.7% (23.2%; 28.4%)
	IVC	536	38.9% (35.0%; 43.3%)	19.7% (16.5%; 23.5%)	13.7% (10.9%; 17.2%)	9.8% (7.4%; 13.0%)	7.3% (5.1%; 10.3%)	4.9% (2.9%; 8.2%)
	X/NA	510	64.1% (59.9%; 68.5%)	49.4% (45.0%; 54.1%)	42.0% (37.6%; 46.8%)	35.9% (31.5%; 40.8%)	33.6% (29.2%; 38.6%)	15.8% (10.4%; 24.0%)
Oropharynx C01;C05.1-C05.9;C09-C10	**All**	5,424	78.3% (77.1%; 79.4%)	66.4% (65.1%; 67.8%)	59.6% (58.2%; 61.1%)	55.0% (53.5%; 56.6%)	50.8% (49.2%; 52.5%)	37.0% (34.5%; 39.7%)
	I	1,033	94.0% (92.4%; 95.7%)	86.9% (84.5%; 89.3%)	82.5% (79.7%; 85.4%)	78.1% (74.8%; 81.4%)	75.3% (71.7%; 79.1%)	58.5% (50.6%; 67.6%)
	II	780	91.1% (88.9%; 93.4%)	82.9% (79.9%; 86.0%)	74.9% (71.4%; 78.7%)	70.7% (66.8%; 74.8%)	65.7% (61.4%; 70.3%)	50.7% (43.2%; 59.6%)
	III	911	81.7% (79.1%; 84.4%)	72.0% (68.9%; 75.2%)	66.9% (63.6%; 70.5%)	62.7% (59.1%; 66.6%)	56.8% (52.9%; 61.0%)	42.9% (36.9%; 49.9%)
	IV	48	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	2,036	71.8% (69.8%; 73.8%)	57.1% (54.9%; 59.4%)	48.8% (46.6%; 51.2%)	44.2% (41.9%; 46.7%)	40.0% (37.6%; 42.5%)	28.8% (25.6%; 32.3%)
	IVC	275	39.7% (34.2%; 46.0%)	19.8% (15.4%; 25.3%)	14.6% (10.8%; 19.9%)	9.9% (6.7%; 14.7%)	8.5% (5.5%; 13.2%)	5.6% (2.8%; 11.2%)
	X/NA	392	66.3% (61.6%; 71.3%)	50.8% (45.9%; 56.3%)	42.8% (37.9%; 48.5%)	36.7% (31.8%; 42.5%)	34.8% (29.8%; 40.7%)	15.4% (9.3%; 25.4%)

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	**All**	472	85.3% (82.0%; 88.7%)	76.5% (72.5%; 80.7%)	72.7% (68.4%; 77.3%)	70.6% (66.1%; 75.5%)	68.1% (63.3%; 73.3%)	61.4% (54.3%; 69.5%)
	I	31	N<50	N<50	N<50	N<50	N<50	N<50
	II	88	94.3% (89.1%; 99.8%)	91.8% (85.0%; 99.2%)	91.2% (83.6%; 99.4%)	90.6% (82.3%; 99.7%)	91.7% (83.3%; 100.9%)	88.1% (74.2%; 104.6%)
	III	147	93.2% (88.9%; 97.6%)	87.3% (81.6%; 93.4%)	83.2% (76.7%; 90.4%)	80.6% (73.4%; 88.4%)	81.5% (74.3%; 89.5%)	76.9% (65.7%; 89.9%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	166	77.7% (71.5%; 84.4%)	67.5% (60.5%; 75.3%)	61.3% (53.9%; 69.8%)	58.2% (50.4%; 67.1%)	52.3% (44.1%; 62.0%)	45.3% (35.6%; 57.5%)
	IVC	8	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	32	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	**All**	2,314	66.6% (64.7%; 68.6%)	52.0% (49.9%; 54.2%)	42.7% (40.5%; 44.9%)	37.3% (35.1%; 39.6%)	33.0% (30.8%; 35.4%)	19.0% (15.8%; 22.8%)
	I	136	89.5% (84.0%; 95.4%)	82.3% (75.3%; 89.9%)	71.8% (63.2%; 81.4%)	61.5% (52.1%; 72.6%)	53.1% (43.2%; 65.2%)	38.4% (23.7%; 62.2%)
	II	188	79.3% (73.4%; 85.7%)	65.9% (58.9%; 73.6%)	54.3% (46.9%; 62.9%)	50.9% (43.2%; 60.0%)	38.9% (30.8%; 49.0%)	21.5% (11.3%; 41.0%)
	III	329	77.8% (73.2%; 82.7%)	64.9% (59.6%; 70.7%)	59.1% (53.4%; 65.4%)	51.5% (45.6%; 58.3%)	49.2% (43.0%; 56.3%)	28.7% (19.8%; 41.6%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,321	66.0% (63.4%; 68.6%)	50.3% (47.5%; 53.2%)	39.8% (37.0%; 42.7%)	34.9% (32.1%; 37.9%)	31.2% (28.4%; 34.3%)	17.8% (13.9%; 22.7%)
	IVC	255	37.8% (32.3%; 44.4%)	19.2% (14.9%; 24.8%)	12.1% (8.5%; 17.2%)	8.9% (5.8%; 13.8%)	5.3% (2.9%; 10.0%)	FU<10 y
	X/NA	88	55.6% (46.0%; 67.2%)	47.3% (37.7%; 59.4%)	40.9% (31.5%; 53.2%)	34.3% (25.2%; 46.9%)	31.1% (22.0%; 43.8%)	15.3% (6.7%; 35.2%)
Larynx (C32)	**All**	4,624	85.7% (84.6%; 86.8%)	78.7% (77.4%; 80.1%)	73.2% (71.6%; 74.8%)	68.5% (66.7%; 70.3%)	65.2% (63.3%; 67.2%)	46.7% (40.9%; 53.3%)
	I	1,709	97.9% (96.8%; 99.0%)	96.2% (94.6%; 97.8%)	92.7% (90.6%; 94.9%)	89.3% (86.4%; 92.2%)	86.4% (83.1%; 89.8%)	66.4% (54.1%; 81.4%)
	II	715	90.3% (87.8%; 92.9%)	82.7% (79.4%; 86.1%)	76.4% (72.6%; 80.5%)	70.9% (66.6%; 75.5%)	66.4% (61.6%; 71.5%)	45.2% (30.7%; 66.4%)
	III	700	81.3% (78.2%; 84.5%)	72.8% (69.2%; 76.6%)	67.3% (63.3%; 71.5%)	61.6% (57.3%; 66.2%)	58.6% (54.0%; 63.6%)	43.2% (35.9%; 51.8%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,075	73.5% (70.8%; 76.3%)	60.9% (57.8%; 64.1%)	52.6% (49.4%; 56.0%)	46.6% (43.3%; 50.2%)	42.3% (38.9%; 46.1%)	25.1% (20.4%; 30.8%)
	IVC	121	46.6% (38.4%; 56.5%)	23.6% (16.9%; 32.8%)	18.1% (12.1%; 26.9%)	17.1% (11.2%; 26.1%)	17.7% (11.6%; 27.1%)	13.4% (6.7%; 26.9%)

Net Survival Probability, 2015-2024								
location	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	303	74.6% (69.5%; 80.0%)	69.7% (64.2%; 75.8%)	63.9% (57.8%; 70.8%)	60.0% (53.4%; 67.5%)	58.1% (51.0%; 66.1%)	40.7% (29.5%; 56.1%)
Nasal cavity and paranasal sinuses (C30-C31)	**All**	979	81.6% (78.9%; 84.3%)	69.2% (66.0%; 72.5%)	63.0% (59.5%; 66.7%)	59.2% (55.4%; 63.2%)	58.9% (54.9%; 63.1%)	51.4% (43.9%; 60.3%)
	I	119	96.2% (91.7%; 101.0%)	89.5% (82.5%; 97.0%)	86.1% (77.8%; 95.4%)	81.0% (71.4%; 91.9%)	82.2% (72.4%; 93.2%)	80.0% (60.6%; 105.7%)
	II	118	97.6% (93.2%; 102.3%)	91.6% (84.6%; 99.0%)	84.2% (75.2%; 94.3%)	86.3% (76.2%; 97.7%)	86.7% (75.5%; 99.4%)	66.5% (34.3%; 129.0%)
	III	121	93.4% (88.0%; 99.1%)	86.5% (79.0%; 94.7%)	74.9% (64.9%; 86.3%)	71.2% (60.4%; 83.9%)	73.9% (62.7%; 87.1%)	52.5% (33.2%; 83.1%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	307	71.5% (66.4%; 77.1%)	55.7% (50.0%; 62.1%)	49.1% (43.2%; 55.8%)	46.2% (40.0%; 53.4%)	44.0% (37.6%; 51.4%)	28.0% (19.7%; 39.9%)
	IVC	46	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	270	80.7% (75.8%; 86.0%)	65.5% (59.6%; 72.1%)	61.5% (55.2%; 68.6%)	55.2% (48.4%; 63.0%)	53.8% (46.8%; 61.9%)	57.7% (48.2%; 69.2%)
Salivary glands (C07-C08)	**All**	768	87.1% (84.4%; 90.0%)	77.0% (73.5%; 80.6%)	71.7% (67.7%; 76.0%)	68.7% (64.3%; 73.4%)	63.9% (58.3%; 70.1%)	57.3% (47.4%; 69.4%)
	I	115	98.0% (95.0%; 101.0%)	98.6% (94.1%; 103.3%)	98.1% (92.4%; 104.2%)	97.8% (90.5%; 105.6%)	91.3% (78.8%; 105.7%)	83.9% (56.5%; 124.8%)
	II	119	96.8% (92.3%; 101.5%)	91.0% (84.3%; 98.3%)	88.2% (80.3%; 96.9%)	85.5% (76.4%; 95.7%)	84.4% (74.1%; 96.1%)	94.5% (81.9%; 109.0%)
	III	104	92.7% (86.8%; 99.1%)	86.3% (77.5%; 96.2%)	78.2% (66.6%; 91.8%)	81.0% (68.3%; 96.0%)	72.5% (54.3%; 96.8%)	49.1% (27.1%; 89.0%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	198	79.9% (73.8%; 86.5%)	60.9% (53.5%; 69.3%)	55.3% (47.5%; 64.4%)	46.1% (37.9%; 56.0%)	42.4% (33.5%; 53.7%)	35.9% (22.7%; 56.8%)
	IVC	69	52.9% (42.0%; 66.7%)	39.6% (29.0%; 54.0%)	28.0% (18.2%; 43.1%)	14.9% (7.4%; 30.3%)	13.4% (6.3%; 28.5%)	FU<10 y
	X/NA	163	89.5% (84.1%; 95.1%)	80.5% (73.5%; 88.0%)	74.6% (66.7%; 83.5%)	75.1% (66.6%; 84.6%)	70.7% (60.1%; 83.3%)	62.7% (48.0%; 81.9%)
Other and ill-defined sites (C14)	**All**	113	56.4% (47.8%; 66.6%)	46.7% (38.1%; 57.3%)	40.5% (31.9%; 51.3%)	33.5% (25.2%; 44.4%)	34.1% (25.7%; 45.3%)	18.1% (10.2%; 32.2%)
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	112	56.0% (47.3%; 66.2%)	46.2% (37.6%; 56.9%)	39.9% (31.3%; 50.8%)	32.8% (24.5%; 43.7%)	33.4% (25.0%; 44.6%)	18.5% (10.4%; 32.8%)
Females								
Head & Neck (C00-C14, C30-C32)	**All**	7,187	81.0% (80.1%; 82.0%)	72.5% (71.4%; 73.7%)	67.9% (66.7%; 69.1%)	64.3% (63.0%; 65.7%)	61.4% (60.0%; 62.9%)	50.2% (47.0%; 53.5%)
	I	1,854	96.3% (95.2%; 97.4%)	94.2% (92.8%; 95.7%)	91.1% (89.2%; 93.0%)	88.2% (86.0%; 90.5%)	87.2% (84.7%; 89.7%)	73.8% (64.7%; 84.3%)
	II	1,157	93.2% (91.5%; 94.9%)	85.7% (83.3%; 88.1%)	81.8% (79.0%; 84.7%)	77.5% (74.3%; 80.9%)	75.1% (71.5%; 78.9%)	66.5% (58.8%; 75.2%)
	III	1,086	82.4% (80.0%; 84.9%)	72.9% (70.0%; 75.9%)	66.1% (63.0%; 69.4%)	62.5% (59.1%; 66.0%)	58.4% (54.8%; 62.2%)	48.1% (41.9%; 55.2%)
	IV	18	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	2,416	68.9% (67.0%; 70.8%)	55.6% (53.5%; 57.7%)	49.4% (47.3%; 51.7%)	45.4% (43.2%; 47.7%)	41.8% (39.5%; 44.3%)	30.0% (26.6%; 33.9%)
	IVC	240	37.9% (32.1%; 44.7%)	23.7% (18.7%; 30.0%)	18.5% (13.9%; 24.7%)	17.5% (12.9%; 23.7%)	15.3% (10.8%; 21.6%)	12.5% (8.0%; 19.6%)
	X/NA	629	74.4% (70.8%; 78.1%)	66.5% (62.7%; 70.7%)	63.5% (59.4%; 67.9%)	57.1% (52.6%; 62.0%)	53.0% (48.3%; 58.2%)	41.6% (35.0%; 49.4%)
Lip (C00)	**All**	168	94.2% (89.4%; 99.2%)	89.2% (82.5%; 96.4%)	86.6% (78.3%; 95.8%)	84.1% (74.3%; 95.1%)	83.7% (72.4%; 96.7%)	87.5% (48.9%; 156.7%)
	I	108	97.1% (92.2%; 102.2%)	97.1% (90.1%; 104.5%)	93.8% (84.3%; 104.5%)	88.9% (77.0%; 102.6%)	90.0% (76.9%; 105.2%)	42.2% (13.9%; 128.6%)
	II	28	N<50	N<50	N<50	N<50	N<50	N<50
	III	8	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	12	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	1	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	11	N<50	N<50	N<50	N<50	N<50	N<50
Oral cavity (C02-C05.0, C06)	**All**	2,523	80.5% (78.8%; 82.1%)	70.2% (68.2%; 72.2%)	66.1% (64.0%; 68.3%)	62.7% (60.4%; 65.1%)	60.2% (57.8%; 62.8%)	57.5% (53.5%; 61.9%)
	I	694	96.3% (94.5%; 98.1%)	93.4% (91.0%; 95.9%)	90.2% (87.1%; 93.3%)	87.0% (83.4%; 90.7%)	84.3% (80.3%; 88.5%)	83.6% (76.9%; 90.9%)
	II	418	92.5% (89.5%; 95.6%)	84.2% (79.9%; 88.7%)	80.4% (75.4%; 85.7%)	77.7% (71.9%; 84.0%)	75.3% (68.7%; 82.7%)	81.0% (68.1%; 96.3%)

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	III	354	83.9% (79.7%; 88.2%)	70.9% (65.9%; 76.4%)	65.8% (60.2%; 71.8%)	59.6% (53.6%; 66.2%)	57.8% (51.5%; 64.8%)	53.7% (43.6%; 66.1%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	951	66.4% (63.3%; 69.6%)	51.4% (48.2%; 54.9%)	46.4% (43.1%; 50.0%)	43.5% (40.0%; 47.3%)	40.9% (37.3%; 45.0%)	34.9% (29.3%; 41.6%)
	IVC	50	45.7% (33.5%; 62.3%)	23.7% (14.3%; 39.2%)	23.2% (13.5%; 39.8%)	21.0% (11.3%; 39.0%)	17.3% (8.3%; 36.0%)	17.3% (8.3%; 36.0%)
	X/NA	100	61.5% (52.3%; 72.4%)	52.4% (42.9%; 64.0%)	48.6% (38.9%; 60.7%)	44.5% (34.6%; 57.3%)	40.4% (30.4%; 53.7%)	25.1% (12.9%; 49.1%)
Pharynx (C01, C05.1-C05.9, C09-C13)	**All**	2,698	77.5% (75.9%; 79.2%)	68.2% (66.4%; 70.1%)	62.9% (60.9%; 64.9%)	58.5% (56.4%; 60.6%)	54.8% (52.6%; 57.1%)	39.2% (35.3%; 43.6%)
	I	500	94.3% (92.1%; 96.6%)	90.9% (88.0%; 94.0%)	86.3% (82.7%; 90.1%)	82.8% (78.7%; 87.2%)	81.5% (77.0%; 86.3%)	54.4% (37.2%; 79.6%)
	II	425	90.8% (87.9%; 93.9%)	81.8% (77.9%; 86.0%)	79.2% (75.0%; 83.7%)	73.4% (68.6%; 78.6%)	71.1% (65.9%; 76.6%)	52.0% (42.9%; 63.0%)
	III	459	79.4% (75.6%; 83.4%)	71.4% (67.1%; 76.0%)	65.5% (60.9%; 70.5%)	62.1% (57.2%; 67.4%)	57.1% (51.9%; 62.9%)	45.9% (38.4%; 54.8%)
	IV	18	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	1,036	70.0% (67.2%; 72.9%)	57.0% (54.0%; 60.3%)	49.8% (46.7%; 53.1%)	45.3% (42.1%; 48.8%)	40.6% (37.3%; 44.1%)	27.7% (23.3%; 33.0%)
	IVC	114	31.9% (24.4%; 41.8%)	22.7% (16.0%; 32.1%)	15.9% (10.1%; 24.9%)	14.7% (9.1%; 23.7%)	11.9% (6.8%; 20.8%)	10.8% (5.8%; 20.3%)
	X/NA	188	69.5% (63.1%; 76.6%)	61.0% (54.2%; 68.8%)	58.0% (50.9%; 66.0%)	48.7% (41.3%; 57.5%)	45.9% (38.4%; 54.9%)	28.8% (20.7%; 40.2%)
Oropharynx C01;C05.1-C05.9;C09-C10	**All**	2,075	79.3% (77.5%; 81.1%)	69.7% (67.6%; 71.8%)	65.1% (62.9%; 67.3%)	61.0% (58.7%; 63.5%)	57.6% (55.1%; 60.2%)	39.6% (34.9%; 44.9%)
	I	449	94.7% (92.3%; 97.1%)	90.7% (87.6%; 93.9%)	86.6% (82.7%; 90.6%)	83.9% (79.5%; 88.4%)	82.7% (77.9%; 87.7%)	50.2% (32.1%; 78.4%)
	II	321	91.3% (88.0%; 94.7%)	81.8% (77.3%; 86.5%)	79.0% (74.1%; 84.3%)	73.2% (67.6%; 79.3%)	71.4% (65.4%; 77.9%)	46.7% (36.1%; 60.4%)
	III	335	80.4% (76.1%; 85.0%)	72.3% (67.3%; 77.7%)	69.2% (63.9%; 74.9%)	66.7% (61.1%; 72.9%)	60.6% (54.5%; 67.4%)	46.1% (37.1%; 57.3%)
	IV	18	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	737	71.3% (68.0%; 74.7%)	57.9% (54.3%; 61.7%)	51.0% (47.4%; 55.0%)	46.6% (42.8%; 50.7%)	42.5% (38.6%; 46.8%)	29.1% (24.0%; 35.4%)
	IVC	75	33.8% (24.6%; 46.3%)	20.7% (13.1%; 32.7%)	13.8% (7.6%; 25.2%)	13.9% (7.6%; 25.4%)	9.4% (4.3%; 20.6%)	7.6% (3.0%; 19.3%)
	X/NA	160	70.8% (64.0%; 78.5%)	62.7% (55.4%; 71.1%)	59.5% (51.9%; 68.2%)	52.6% (44.5%; 62.2%)	50.0% (41.7%; 59.9%)	33.1% (24.2%; 45.4%)

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Nasopharynx C11	**All**	191	86.9% (82.1%; 92.0%)	82.6% (77.1%; 88.4%)	78.8% (72.8%; 85.3%)	76.4% (70.0%; 83.4%)	75.3% (68.6%; 82.6%)	67.6% (56.7%; 80.6%)
	I	13	N<50	N<50	N<50	N<50	N<50	N<50
	II	52	96.7% (91.5%; 102.1%)	95.8% (89.5%; 102.7%)	90.1% (81.1%; 100.1%)	85.5% (74.7%; 97.7%)	86.1% (75.3%; 98.5%)	80.4% (61.9%; 104.6%)
	III	51	86.5% (77.3%; 96.8%)	80.8% (70.3%; 92.9%)	76.5% (65.1%; 89.9%)	77.0% (65.5%; 90.4%)	74.0% (61.5%; 88.9%)	77.7% (64.6%; 93.4%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	62	81.1% (71.7%; 91.6%)	74.9% (64.6%; 86.8%)	75.4% (65.0%; 87.4%)	76.1% (65.6%; 88.2%)	74.1% (62.9%; 87.3%)	59.0% (42.2%; 82.4%)
	IVC	5	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	8	N<50	N<50	N<50	N<50	N<50	N<50
Hypopharynx C12-C13	**All**	462	65.6% (61.3%; 70.2%)	55.3% (50.8%; 60.3%)	45.7% (41.1%; 50.9%)	38.1% (33.5%; 43.4%)	31.7% (27.1%; 37.1%)	25.4% (20.1%; 32.1%)
	I	41	N<50	N<50	N<50	N<50	N<50	N<50
	II	54	82.4% (72.3%; 93.9%)	67.6% (55.6%; 82.2%)	68.5% (56.3%; 83.2%)	62.1% (49.2%; 78.4%)	54.2% (40.7%; 72.1%)	52.2% (36.6%; 74.3%)
	III	73	69.6% (59.6%; 81.3%)	60.7% (50.1%; 73.5%)	41.5% (31.0%; 55.4%)	31.2% (21.3%; 45.5%)	30.3% (20.4%; 45.0%)	24.5% (13.3%; 44.9%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	240	62.9% (56.9%; 69.4%)	50.1% (44.0%; 57.2%)	39.5% (33.4%; 46.7%)	33.9% (27.9%; 41.1%)	25.7% (19.9%; 33.1%)	15.2% (9.5%; 24.2%)
	IVC	34	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	20	N<50	N<50	N<50	N<50	N<50	N<50
Larynx (C32)	**All**	905	85.1% (82.7%; 87.6%)	77.8% (74.9%; 80.8%)	70.9% (67.6%; 74.3%)	66.4% (62.7%; 70.2%)	63.1% (59.2%; 67.2%)	45.7% (38.8%; 53.9%)
	I	308	96.0% (93.2%; 98.8%)	94.6% (91.0%; 98.2%)	92.0% (87.7%; 96.6%)	89.3% (84.0%; 95.0%)	89.4% (83.5%; 95.7%)	70.5% (56.3%; 88.3%)
	II	136	92.2% (87.5%; 97.1%)	83.7% (77.2%; 90.7%)	73.8% (66.0%; 82.5%)	66.1% (57.6%; 75.9%)	61.6% (52.6%; 72.1%)	51.1% (39.7%; 65.9%)
	III	176	83.7% (78.0%; 89.8%)	75.0% (68.4%; 82.4%)	64.0% (56.3%; 72.6%)	61.0% (52.9%; 70.4%)	53.0% (44.2%; 63.6%)	38.8% (25.4%; 59.3%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	205	70.6% (64.4%; 77.3%)	58.0% (51.4%; 65.5%)	50.3% (43.4%; 58.2%)	44.3% (37.4%; 52.5%)	41.5% (34.4%; 50.0%)	17.8% (9.9%; 32.1%)
	IVC	26	N<50	N<50	N<50	N<50	N<50	N<50

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	55	77.6% (67.1%; 89.8%)	70.2% (58.4%; 84.4%)	63.8% (51.4%; 79.3%)	57.7% (43.8%; 76.1%)	49.5% (35.5%; 68.9%)	32.5% (19.4%; 54.4%)
Nasal cavity and paranasal sinuses (C30-C31)	**All**	415	81.8% (77.9%; 86.0%)	74.1% (69.5%; 79.1%)	69.4% (64.3%; 74.9%)	67.0% (61.6%; 72.9%)	63.5% (57.6%; 70.1%)	48.2% (39.0%; 59.6%)
	I	73	96.0% (90.8%; 101.5%)	97.6% (92.4%; 103.2%)	95.0% (87.4%; 103.3%)	95.0% (86.7%; 104.1%)	97.0% (88.6%; 106.3%)	87.7% (71.1%; 108.1%)
	II	34	N<50	N<50	N<50	N<50	N<50	N<50
	III	31	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	117	66.7% (58.2%; 76.5%)	55.3% (45.9%; 66.6%)	48.6% (38.9%; 60.6%)	44.2% (34.4%; 56.8%)	41.5% (31.2%; 55.2%)	36.9% (25.0%; 54.6%)
	IVC	17	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	143	86.2% (80.3%; 92.6%)	76.4% (69.1%; 84.4%)	76.3% (68.7%; 84.7%)	72.8% (64.5%; 82.3%)	65.0% (55.7%; 76.0%)	40.8% (28.9%; 57.6%)
Salivary glands (C07-C08)	**All**	602	90.6% (88.0%; 93.3%)	88.1% (85.0%; 91.4%)	86.8% (83.2%; 90.5%)	84.8% (80.6%; 89.3%)	84.1% (79.3%; 89.1%)	67.7% (53.9%; 85.1%)
	I	188	99.4% (97.9%; 101.0%)	100.7% (98.8%; 102.7%)	100.4% (97.3%; 103.5%)	100.9% (97.2%; 104.8%)	102.5% (97.9%; 107.4%)	89.6% (57.8%; 138.8%)
	II	123	99.8% (97.5%; 102.3%)	101.1% (97.5%; 104.8%)	100.3% (95.0%; 105.9%)	98.2% (90.9%; 106.2%)	97.3% (88.3%; 107.3%)	67.8% (41.8%; 110.1%)
	III	62	87.9% (79.1%; 97.7%)	85.6% (75.8%; 96.7%)	85.0% (73.7%; 97.9%)	87.9% (76.3%; 101.3%)	84.3% (70.9%; 100.2%)	60.4% (35.8%; 101.8%)
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVA-B	107	81.5% (73.8%; 90.0%)	73.2% (64.0%; 83.7%)	70.5% (60.6%; 82.0%)	64.3% (53.3%; 77.5%)	62.4% (50.5%; 77.0%)	42.4% (26.8%; 66.8%)
	IVC	32	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	91	89.1% (82.0%; 96.8%)	87.2% (78.7%; 96.6%)	84.3% (74.7%; 95.2%)	79.0% (66.8%; 93.5%)	76.3% (63.3%; 92.0%)	78.4% (58.6%; 104.8%)
Other and ill-defined sites (C14)	**All**	44	N<50	N<50	N<50	N<50	N<50	N<50
	I	0	N<50	N<50	N<50	N<50	N<50	N<50
	II	0	N<50	N<50	N<50	N<50	N<50	N<50
	III	0	N<50	N<50	N<50	N<50	N<50	N<50
	IV	0	N<50	N<50	N<50	N<50	N<50	N<50

location	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	IVA-B	0	N<50	N<50	N<50	N<50	N<50	N<50
	IVC	0	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	44	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Head & Neck cancer survival trends: by tumour stage

5.1.1. Head & Neck cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	11257	78.4% (77.6%; 79.2%)	58.8% (57.8%; 59.8%)	50.2% (49.1%; 51.3%)	3354	80.3% (78.9%; 81.8%)	64.2% (62.4%; 66.0%)	56.6% (54.7%; 58.6%)
	I	1683	97.8% (96.7%; 98.9%)	89.6% (87.5%; 91.7%)	82.3% (79.6%; 85.2%)	526	96.1% (94.1%; 98.1%)	86.1% (82.5%; 89.8%)	79.2% (74.9%; 83.8%)
	II	1192	91.2% (89.4%; 93.1%)	71.2% (68.3%; 74.2%)	62.5% (59.2%; 65.9%)	394	89.0% (85.6%; 92.4%)	76.3% (71.7%; 81.2%)	67.5% (62.1%; 73.4%)
	III	1506	83.2% (81.2%; 85.2%)	61.9% (59.3%; 64.7%)	50.8% (48.1%; 53.8%)	416	83.0% (79.3%; 86.9%)	64.4% (59.6%; 69.6%)	57.4% (52.3%; 63.0%)
	IV	0	N<50	N<50	N<50	0	N<50	N<50	N<50
	IVA-B	3586	69.8% (68.3%; 71.4%)	43.8% (42.1%; 45.5%)	34.4% (32.8%; 36.2%)	905	72.5% (69.6%; 75.6%)	49.8% (46.5%; 53.3%)	40.9% (37.6%; 44.5%)
	IVC	424	45.4% (40.9%; 50.5%)	15.3% (12.1%; 19.4%)	8.7% (6.2%; 12.1%)	78	49.3% (39.3%; 61.7%)	26.4% (18.2%; 38.4%)	19.1% (12.0%; 30.3%)
	X/NA	2943	74.0% (72.4%; 75.7%)	58.1% (56.1%; 60.1%)	50.4% (48.3%; 52.6%)	1055	76.8% (74.1%; 79.5%)	63.5% (60.3%; 66.9%)	57.0% (53.5%; 60.7%)
2010-2014	All	9610	78.9% (78.0%; 79.8%)	60.1% (59.0%; 61.2%)	51.7% (50.5%; 52.9%)	3248	81.4% (80.0%; 82.9%)	66.3% (64.5%; 68.1%)	59.7% (57.7%; 61.7%)
	I	1902	95.2% (94.0%; 96.4%)	87.6% (85.6%; 89.6%)	82.4% (79.9%; 84.9%)	718	97.1% (95.5%; 98.7%)	89.6% (86.8%; 92.6%)	85.9% (82.4%; 89.5%)
	II	1187	87.2% (85.1%; 89.3%)	72.2% (69.3%; 75.2%)	62.5% (59.2%; 66.0%)	446	88.8% (85.6%; 92.1%)	75.5% (70.9%; 80.3%)	68.9% (63.8%; 74.5%)
	III	1350	81.1% (78.9%; 83.3%)	60.6% (57.8%; 63.5%)	51.9% (48.9%; 55.1%)	411	86.5% (83.0%; 90.2%)	70.6% (65.8%; 75.8%)	58.6% (53.1%; 64.6%)
	IV	0	N<50	N<50	N<50	0	N<50	N<50	N<50
	IVA-B	3518	72.6% (71.1%; 74.2%)	46.9% (45.1%; 48.7%)	36.4% (34.6%; 38.2%)	1064	72.1% (69.4%; 75.0%)	50.6% (47.5%; 53.9%)	43.2% (40.0%; 46.7%)
	IVC	381	46.3% (41.5%; 51.8%)	18.4% (14.8%; 23.0%)	10.6% (7.7%; 14.8%)	104	46.3% (37.5%; 57.1%)	22.1% (14.7%; 33.5%)	20.1% (12.9%; 31.3%)

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	X/NA	1426	72.1% (69.7%; 74.6%)	55.3% (52.5%; 58.3%)	48.0% (44.9%; 51.4%)	545	75.1% (71.3%; 79.1%)	61.1% (56.5%; 66.1%)	54.5% (49.5%; 60.1%)
2015-2019	All	9694	79.6% (78.7%; 80.4%)	61.8% (60.8%; 62.9%)	53.7% (52.5%; 54.9%)	3514	79.7% (78.3%; 81.2%)	66.5% (64.8%; 68.2%)	59.4% (57.5%; 61.3%)
	I	2019	97.0% (96.0%; 98.1%)	88.6% (86.7%; 90.6%)	81.5% (78.9%; 84.2%)	836	95.6% (93.9%; 97.3%)	89.7% (86.9%; 92.6%)	84.8% (81.4%; 88.4%)
	II	1297	90.5% (88.7%; 92.3%)	75.6% (72.9%; 78.4%)	65.8% (62.6%; 69.1%)	528	92.9% (90.4%; 95.5%)	81.5% (77.6%; 85.7%)	74.2% (69.5%; 79.2%)
	III	1452	83.4% (81.4%; 85.5%)	67.5% (64.9%; 70.3%)	59.3% (56.2%; 62.5%)	503	84.2% (80.8%; 87.7%)	67.2% (62.7%; 71.9%)	58.7% (53.8%; 64.0%)
	IV	6	N<50	N<50	N<50	2	N<50	N<50	N<50
	IVA-B	3678	71.3% (69.8%; 72.8%)	47.3% (45.7%; 49.1%)	38.5% (36.8%; 40.3%)	1230	67.1% (64.5%; 69.9%)	48.2% (45.3%; 51.2%)	40.7% (37.8%; 43.9%)
	IVC	475	40.3% (36.0%; 45.0%)	14.0% (11.1%; 17.8%)	9.3% (6.8%; 12.5%)	110	34.2% (26.3%; 44.4%)	16.1% (10.4%; 24.8%)	12.2% (7.3%; 20.4%)
	X/NA	981	72.3% (69.4%; 75.3%)	53.9% (50.5%; 57.5%)	46.5% (42.9%; 50.3%)	369	73.7% (69.1%; 78.6%)	65.2% (59.9%; 70.8%)	53.2% (47.4%; 59.7%)
2020-2024	All	9209	80.6% (79.7%; 81.5%)	64.9% (63.8%; 66.1%)	56.4% (54.9%; 57.9%)	3765	82.3% (81.0%; 83.6%)	69.0% (67.3%; 70.8%)	63.8% (61.6%; 66.1%)
	I	2282	96.3% (95.3%; 97.4%)	89.0% (87.1%; 91.0%)	82.4% (79.4%; 85.5%)	1032	96.7% (95.3%; 98.1%)	92.0% (89.5%; 94.5%)	89.2% (85.6%; 92.8%)
	II	1411	90.4% (88.6%; 92.2%)	76.9% (74.1%; 79.7%)	67.5% (63.7%; 71.6%)	634	93.2% (90.9%; 95.5%)	82.0% (78.1%; 86.1%)	76.2% (70.0%; 82.9%)
	III	1562	82.5% (80.5%; 84.5%)	67.6% (64.8%; 70.4%)	58.9% (55.3%; 62.7%)	585	80.9% (77.5%; 84.4%)	65.2% (60.9%; 69.9%)	59.0% (53.6%; 64.9%)
	IV	43	N<50	N<50	N<50	16	N<50	N<50	N<50
	IVA-B	3155	70.9% (69.3%; 72.6%)	48.1% (46.2%; 50.1%)	37.9% (35.6%; 40.4%)	1190	70.8% (68.1%; 73.5%)	50.7% (47.6%; 54.0%)	43.7% (39.9%; 47.8%)
	IVC	424	41.8% (37.3%; 46.9%)	19.1% (15.3%; 23.8%)	11.5% (7.9%; 16.7%)	130	41.0% (33.2%; 50.6%)	20.8% (14.2%; 30.3%)	19.0% (11.9%; 30.4%)
	X/NA	549	69.6% (65.7%; 73.8%)	54.0% (49.4%; 59.1%)	47.8% (41.3%; 55.3%)	261	75.4% (70.1%; 81.1%)	60.1% (53.7%; 67.4%)	53.4% (45.6%; 62.6%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Head & Neck cancer mortality: by region

6.1.1. Head & Neck cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**
Males																					
Belgium	0	0	0	0	0	0	0	0	3	7	23	40	76	84	73	63	43	31	12	4	459	8.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.9]	[5.8]	[9.9]	[20.3]	[26.4]	[27.4]	[31.0]	[34.4]	[38.9]	[38.3]	[66.0]	[8.0]	(7.6; 9.2)
Brussels	0	0	0	0	0	0	0	0	0	1	2	5	9	8	9	7	2	0	2	0	45	11.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[4.9]	[14.1]	[31.2]	[37.5]	[53.5]	[55.4]	[24.9]	[0.0]	[86.8]	[0.0]	[7.4]	(8.1; 15.0)
Flanders	0	0	0	0	0	0	0	0	3	5	14	23	45	51	46	42	34	25	6	4	298	8.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[2.4]	[6.1]	[9.5]	[19.7]	[26.0]	[28.0]	[32.2]	[41.2]	[46.5]	[28.8]	[100.8]	[8.9]	(7.8; 9.8)
Wallonia	0	0	0	0	0	0	0	0	0	1	7	12	22	25	18	14	7	6	4	0	116	6.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[5.6]	[9.6]	[18.8]	[24.8]	[21.1]	[23.2]	[20.4]	[28.7]	[48.6]	[0.0]	[6.4]	(5.6; 8.1)
Females																					
Belgium	0	0	0	0	0	0	0	0	1	2	6	17	23	31	26	28	19	18	16	8	195	2.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.5]	[1.5]	[4.3]	[6.0]	[9.2]	[8.8]	[11.4]	[10.9]	[13.5]	[22.6]	[38.4]	[3.3]	(2.5; 3.3)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	2	3	1	0	0	12	2.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.3]	[12.0]	[9.3]	[11.1]	[23.4]	[10.2]	[0.0]	[0.0]	[1.9]	(1.1; 3.9)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	0	0	0	2	6	14	10	14	18	19	8	13	15	8	127	3.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[2.7]	[5.9]	[4.4]	[6.9]	[10.3]	[12.6]	[7.3]	[15.2]	[34.1]	[65.3]	[3.7]	(2.6; 3.7)
Wallonia	0	0	0	0	0	0	0	0	1	0	0	3	12	14	6	7	8	4	1	0	56	2.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[2.4]	[9.8]	[12.6]	[6.0]	[9.0]	[15.4]	[10.3]	[4.7]	[0.0]	[3.0]	(2.0; 3.4)

7.1. Head & Neck cancer mortality trends: by region

7.1.1. Head & Neck cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	595	634	610	567	592	609	585	572	624	642	626	600	601	565	545	544	553	506	483	459		
	CR	11.7	12.4	11.9	10.9	11.3	11.6	11.0	10.7	11.5	11.8	11.4	10.9	10.9	10.1	9.7	9.7	9.8	8.9	8.5	8.0		
	ESR2013	14.3	14.8	14.2	13.0	13.1	13.3	13.0	12.3	13.3	13.8	12.8	12.2	12.3	11.1	10.6	10.6	10.5	9.6	9.0	8.4	-2.6 (-2.9; -2.3)	2004-2023
																						-1.1 (-1.7; -0.5)	2004-2015
																						-4.5 (-5.3; -3.7)	2016-2023
Brussels	**N**	58	52	60	61	56	57	49	53	65	54	55	53	53	53	50	53	38	37	40	45		
	CR	12.1	10.8	12.3	12.3	11.1	11.0	9.3	9.8	11.8	9.6	9.7	9.3	9.1	9.1	8.5	8.9	6.4	6.2	6.7	7.4		
	ESR2013	17.1	15.9	17.7	17.7	16.0	15.6	13.9	15.5	17.5	15.7	15.1	14.9	15.6	13.7	13.6	13.8	10.0	10.0	10.8	11.6	-2.6 (-3.3; -1.9)	2004-2023
																						-0.9 (-2.3; 0.4)	2004-2015
																						-4.9 (-6.7; -3.0)	2016-2023
Flanders	**N**	362	354	346	327	318	340	350	341	348	372	384	391	376	348	327	328	344	320	290	298		
	CR	12.2	11.9	11.5	10.8	10.5	11.1	11.3	11.0	11.1	11.8	12.1	12.3	11.7	10.8	10.1	10.1	10.5	9.7	8.7	8.9		
	ESR2013	14.8	13.7	13.4	12.4	11.7	12.4	12.7	11.9	12.3	13.0	12.8	12.8	12.3	11.2	10.2	10.4	10.5	9.7	8.6	8.8	-2.4 (-2.8; -1.9)	2004-2023
																						-1.1 (-1.8; -0.4)	2004-2017
																						-5.0 (-6.6; -3.4)	2018-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Wallonia	**N**	175	228	204	179	218	212	186	178	211	216	187	156	172	164	168	163	171	149	153	116		
	CR	10.7	13.8	12.3	10.7	13.0	12.6	10.9	10.4	12.2	12.5	10.7	8.9	9.8	9.3	9.5	9.2	9.6	8.3	8.5	6.4		
	ESR2013	12.8	16.5	14.8	13.0	15.3	14.4	13.2	12.4	14.2	14.7	12.3	10.0	11.2	10.5	10.7	10.4	10.7	9.2	9.4	6.9	-2.8 (-3.6; -1.9)	2004-2023
																						0.0 (-3.1; 3.3)	2004-2010
																						-4.0 (-5.3; -2.8)	2011-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Head & Neck cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	173	152	149	154	162	163	169	171	183	191	177	203	191	222	174	195	151	173	188	195		
	CR	3.3	2.8	2.8	2.9	3.0	3.0	3.1	3.1	3.3	3.4	3.1	3.6	3.3	3.9	3.0	3.4	2.6	3.0	3.2	3.3		
	ESR2013	3.3	2.9	2.9	2.9	3.0	2.9	3.1	3.1	3.3	3.4	3.1	3.4	3.2	3.7	2.8	3.1	2.4	2.8	2.8	2.9	-0.5 (-1.1; 0.2)	2004-2023
																						0.9 (-0.3; 2.3)	2004-2015
																						-2.3 (-4.1; -0.5)	2016-2023
Brussels	**N**	28	23	20	20	15	18	17	18	20	14	15	19	28	27	12	16	13	17	16	12		
	CR	5.4	4.4	3.8	3.7	2.8	3.3	3.0	3.1	3.4	2.4	2.5	3.2	4.6	4.4	2.0	2.6	2.1	2.7	2.6	1.9		
	ESR2013	5.9	4.5	4.6	4.3	2.9	3.9	3.1	3.6	4.4	2.9	3.1	4.0	5.9	5.8	2.4	3.3	2.6	3.4	2.9	2.5	-2.3 (-4.3; -0.3)	2004-2023
Flanders	**N**	75	78	68	85	86	86	89	87	98	112	94	114	115	121	103	108	104	110	115	127		
	CR	2.5	2.5	2.2	2.7	2.8	2.7	2.8	2.7	3.0	3.5	2.9	3.5	3.5	3.7	3.1	3.2	3.1	3.3	3.4	3.7		
	ESR2013	2.5	2.6	2.2	2.7	2.7	2.6	2.8	2.7	3.0	3.3	2.8	3.2	3.2	3.3	2.7	2.9	2.7	2.9	2.8	3.1	1.1 (0.5; 1.6)	2004-2023
																						2.9 (1.5; 4.3)	2004-2013
																						-0.5 (-1.8; 0.7)	2014-2023
Wallonia	**N**	70	51	61	49	61	59	63	66	65	65	68	70	48	74	59	71	34	46	57	56		
	CR	4.0	2.9	3.5	2.8	3.4	3.3	3.5	3.6	3.6	3.6	3.7	3.8	2.6	4.0	3.2	3.8	1.8	2.5	3.0	3.0		
	ESR2013	4.1	3.1	3.6	2.9	3.5	3.3	3.4	3.7	3.5	3.7	3.6	3.7	2.5	3.9	3.0	3.6	1.7	2.3	2.8	2.7	-1.9 (-3.3; -0.4)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026